CV F. Van Bambeke; Page 1 of 36 - az-most.ru · CV F. Van Bambeke; Page 1 of 36 ... and treasurer...

CV F. Van Bambeke; of 36

Françoise Van Bambeke Pharmacologie cellulaire et moléculaire

Louvain Drug Research Institute & Centre de Pharmacie clinique

Université catholique de Louvain Avenue Mounier 73 B1.73.05

1200 Brussels; Belgium

Email: [email protected]

Web page: http://www.facm.ucl.ac.be/

University degrees

- 1991: Pharmacist (PharmD), Université catholique de Louvain, Belgium - 1995: Doctor in Pharmaceutical Sciences (PhD), Université catholique de Louvain, Belgium - 1997: post-doctoral stay at the Institut Pasteur, Paris, France, in the field of antibiotic resistance - 2005: Agrégée de l’enseignement supérieur (University thesis), Université catholique de Louvain, Belgium

Current position

Senior Research Associate of the Fonds National belge de la Recherche Scientifique ; Extra-ordinary Professor at the Université catholique de Louvain Main research activities:

- Cellular pharmacokinetics, pharmacodynamics and toxicodynamics of antibiotics - Antibiotic resistance, mainly mediated by efflux pumps - Pharmacological evaluation of new antibiotics in in vitro models (cultured cells). Teaching activities

- Pharmacology and pharmacotherapy (to students in Pharmacy) - Infectious diseases and anti-infective pharmacology (to post-graduate students) Scientific publications

Author or co-author of more than 125 peer-reviewed papers. See < http://www.facm.ucl.ac.be/publicat_facm.htm > for a full list. H-index scopus (October 2013): 31; Google scholar (October 2013) : 32 Member of scientific societies

- Société belge de Biologie Cellulaire (since 1994) - Société belge des Sciences Pharmaceutiques (since 1995) - Société belge d'Infectiologie et de Microbiologie Clinique (since 1997) - International Society for Anti-infective Pharmacology (since 1997); secretary since 2012 - American Society for Microbiology (since 1999) - European Society of Clinical Microbiology and Infectious Diseases (since 2008) and treasurer or the ESCMID PK/PD of Anti-Infectives Study Group (since 2010) - Expert in pharmacology for the Belgian National Antibiotic Committee (since 2010) Conferences - 26 in Belgium and 29 in international meetings including the most prestigious ones in the

field of anti-infective pharmacology (ICAAC and ECCMID) and 2 Gordon Research Conferences (2010 and 2011); see http://www.facm.ucl.ac.be/facm-conferences.htm for conferences by members of the unit

- Chairwoman at ICCAC in 2009 and at ECCMID in 2011 - Member of the ECCMID program committee for 2012


Prizes - 1997: Prize form the Belgian Society for Infectiology and Infectious Diseases - 2013: Scientific Award in Infectiology from the Foundation AstraZeneca Member of editorial boards of scientific journals - Chemotherapy (since 2005) - Recent Patents on Anti -Infective Drug Discovery (since 2006) - Antibiotics (since 2012) - Pharmactuel (since 2012) - Journal of Antibiotics ; section editor (since 2013) + regular reviewer for several international journals :: Antimicrob. Ag. Chemother., J. Antimicrob. Chemother, Int. J. Antimicrob. Chemother, PloS one, BMC series, Expert Opinion series, Drugs, Drug Safety,...


Enclosure I: Publications see: http://www.facm.ucl.ac.be/publicat_facm.htm for the corresponding pdf International research papers

N Reference Impact factor

1 Van Bambeke, F., M.P. Mingeot-Leclercq, A. Schanck, R. Brasseur & P.M. Tulkens. 1993. Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells. Eur. J. Pharmacol. 247, 155-168.

2.677

2 Van Bambeke, F., P.M. Tulkens, R. Brasseur & M.P. Mingeot-Leclercq. 1995. Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes. Eur J. Pharmacol. 289, 321-333.

2.637

3 Van Bambeke, F., M.P. Mingeot-Leclercq, P.M. Tulkens, R. Brasseur & A. Schanck. 1996. Aminoglycoside antibiotics prevent the formation of mobile structures in negatively-charged membranes. Comparative studies using fusogenic [bis(ß-diethylaminoethyl-hexestrol)] and aggregating [spermine] agents. Chem. Phys. Lipids 79, 123-135.

2.118

4 Van Bambeke, F., J.P. Montenez, J. Piret, P.M. Tulkens & M.P. Mingeot-Leclercq. 1996. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of phospholipase A1 activity. Eur. J. Pharmacol. 314, 203-214.

2.339

5 Montenez, J.P., F. Van Bambeke, J. Piret, A. Schanck, R. Brasseur, P.M. Tulkens & M.P. Mingeot-Leclercq. 1996. Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. Eur. J. Pharmacol. 314, 215-227.

2.339

6 Gerbaux, C., F. Van Bambeke, J.P. Montenez, J. Piret, G. Morlighem & P.M. Tulkens. 1996. Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional cellular accumulation. FEBS Lett. 394, 307-310.

3.750

7 Van Bambeke F., J.M. Michot, C. Gerbaux, J.P. Montenez, M. Bouvier d'Yvoire & P.M. Tulkens. 1998. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. J. Antimicrob. Chemother. 42, 761-767.

2.563

8 Van Bambeke, F., M. Chauvel, P.E. Reynolds, H.S. Fraimow & P. Courvalin. 1999. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants. Antimicrob. Agents Chemother. 43, 41-47.

3.761

9 Montenez J.P., F. Van Bambeke, J. Piret, R. Brasseur, P.M. Tulkens & M.P. Mingeot-Leclercq. 1999. Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol. Applied Pharmacol. 156, 129-140.

2.654

10 Van Bambeke, F., A. Kerkhofs, A. Schanck, C. Remacle, E. Sonveaux, P.M. Tulkens & M.P. Mingeot-Leclercq. 2000 Biophysical studies and intracellular destabilization of pH-sensitive liposomes. Lipids. 35, 213-223

2.004

11 Prévost, M., D. Van Belle, P.M. Tulkens, P. Courvalin & F. Van Bambeke. 2000. Modeling of the Enterococcus faecalis D-Alanine-D-Alanine ligase: Structure-based study of the active site in the wild-type enzyme and in glycopeptide-dependent mutants. J Mol Microbiol Biotechnol 2, 321-330

(new journal)

12 Gholizadeh, Y., M. Prévost, F. Van Bambeke, B. Casadewall, P.M. Tulkens, & P. Courvalin. 2001. Sequencing of the ddl Gene and Modeling of the mutated D-alanine:D-alanine Ligase in Glycopeptide-Dependent Enterococcus faecium. Prot. Sci. 10, 836-844

4.457

13 Tyteca D., P. Van Der Smissen, F. Van Bambeke, K. Leys, P.M. Tulkens, P.J. Courtoy & M.P. Mingeot-Leclercq. 2001. Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts. Eur J Cell Biol 80:466-478.

3.034


14 Mingeot-Leclercq, M.P., X. Gallet, C. Flore, F. Van Bambeke, J. Peuvot, & R. Brasseur.. 2001. Experimental and conformational analysis of the interactions between butenafine and lipids. Antimicrob Agents Chemother 45:3347-3354

3.954

15 Carryn, S., F. Van Bambeke, M.P. Mingeot-Leclercq & P.M. Tulkens. 2002. Comparative Intracellular (THP-1 Macrophage) and Extracellular Activities of Beta-Lactams, Azithromycin, Gentamicin, and Fluoroquinolones Against Listeria Monocytogenes at Clinically Relevant Concentrations. Antimicrob Agents Chemother 46: 2095-2103.

4.562

16 Tyteca, D., P. Van Der Smissen, M. Mettlen, F. Van Bambeke, P.M. Tulkens, M.P. Mingeot-Leclercq & P.J. Courtoy. 2002. Azithromycin inhibits clathrin-dependent pinocytosis and slows down sequestration of ligand-receptor complexes into endocytic and recycling vesicles in J774 macrophages. Exp. Cell Research. 281: 86-100

5.096

17 Mingeot-Leclercq, M.P., L. Lins, M. Bensliman, F. Van Bambeke, P. Van der Smissen, J.Peuvot, A. Schanck & R. Brasseur. 2002. Membrane destabilization induced by -amyloid peptide 29-42: importance of the amino-terminus. Chem Phys Lipids . 120: 57-74

2.164

18 Mingeot-Leclercq, M.P., L. Lins, M. Bensliman, A. Thomas, F. Van Bambeke, J. Peuvot, A. Schanck & R. Brasseur R. 2003. Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochim Biophys Acta. 1609:28-38

3.010

19 Seral, C., J.M. Michot, H. Chanteux, M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke. 2003. Influence of P-glycoprotein Inhibitors on the accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother. 47: 1047-1051

4.562

20 S. Carryn, F. Van Bambeke, M.P. Mingeot-Leclercq & P.M. Tulkens. 2003. Activity of -Lactams (ampicillin, meropenem), gentamicin, azithromycin and fluoroquinolones (ciprofloxacin, moxifloxacin) against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophages model. J. Antimicrob. Chemother. 51:1051-1052

3.329

21 C. Seral, S. Carryn, P.M. Tulkens & F. Van Bambeke. 2003. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J. Antimicrob. Chemother. 51:1167-1173

3.490

22 Seral C., F. Van Bambeke & P.M. Tulkens. 2003. Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular Staphylococcus aureus in Mouse J774 Macrophages. Antimicrob Agents Chemother. 47: 2283-2292

4.215

23 Chanteux H., M.P. Mingeot-Leclercq, E. Sonveaux, F. Van Bambeke & P.M. Tulkens. 2003. Intracellular accumulation and activity of ampicillin used as free drug and as its phthalimidomethylester [PIMA] or pivaloyloxymethyl ester (pivampicillin [PIVA]) against Listeria monocytogenes in J774 macrophages. J. Antimicrob. Chemother. 52:610-615

3.329

24 Nassogne MC, C. Lizarraga, F. N'Kulia, F. Van Bambeke, R. Van Binst, P. Wallemacq, P.M. Tulkens, M.P. Mingeot-Leclercq, T. Levade & P. J. Courtoy. 2004. Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. Toxicol. Appl. Pharm. 194 :101-110

2.993

25 Michot J.M., F. Van Bambeke, M.P. Mingeot-Leclercq, & P.M. Tulkens.2004. Efflux of the fluoroquinolone antibiotic ciprofloxacin from J774 macrophages through MRP-like transporter. Antimicrob. Agents Chemother. 48:2673-2682

4.215

26 Carryn, S. S. Vandevelde, F. Van Bambeke, M.P. Mingeot-Leclercq, & P.M. Tulkens.2004. Impairment of Listeria monocytogenes growth in THP-1 macrophages by Granulocyte-Macrophage Colony Stimulating Factor. Roles of TNF-a and Nitric Oxide Release. J. Infect. Dis. 189: 2101-2109

4.857

27 Ben Abdelaziz A, S. Lemaire, S. Carryn, F. Van Bambeke, M.P. Mingeot-Leclercq, & P.M. Tulkens. 2004. Inhibition of TNF-alpha production in THP-1 macrophages by glatiramer acetate does not alter their susceptibility to infection by Listeria monocytogenes and does not impair the efficacy of ampicillin or moxifloxacin against intracellular bacteria." J. Antimicrob. Chemother. 54:288-289

3.329


28 Van Bambeke F, S. Carryn, C. Seral, H. Chanteux, D. Tyteca, M.P. Mingeot-Leclercq & P.M. Tulkens. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48: 2853-2860.

4.246

29 Chanteux H., F. Van Bambeke, M.P. Mingeot-Leclercq & P.M. Tulkens. 2005. Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethyl ester prodrug (pivampicillin). Antimicrob. Agents Chemother. 49:1279-88

4.246

30 Servais H., P. Van Der Smissen, G. Thirion, G. Van der Essen, F. Van Bambeke, P.M. Tulkens, & M-P. Mingeot-Leclercq. 2005. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol. Appl. Pharmacol., 15:321-333

2.993

31 Van Bambeke, F., J. Saffran, M-P. Mingeot-Leclercq & P.M. Tulkens. 2005. Mixed lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob. Agents Chemother. 49:1695-700.

4.246

32 Seral, C., M. Barcia-Macay, M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke. 2005. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin, and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J. Antimicrob. Chemother. 55: 511-517.

3.080

33 Piret, J., A. Schank, S. Delfosse, F. Van Bambeke, B.K. Kishore, P.M. Tulkens & M.P. Mingeot-Leclercq. 2005. Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. Chem. Phys. Lipids 133:1-15.

2.164

34 Lemaire, S., F. Van Bambeke, M.P. Mingeot-Leclercq, & Paul M. Tulkens Activity of 3 beta-lactams (ertapenem, meropenem, and ampicillin) against intraphagocytic L. monocytogenes and S. aureus. J. Antimicrob. Chemother.55:897-904.

3.080

35 Michot J.M., C. Seral, F. Van Bambeke, M.P. Mingeot-Leclercq & P.M. Tulkens. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother. 49:2429-37.

4.246

36 Charvalos E., M.N. Tzatzarakis, F. Van Bambeke, P.M. Tulkens, A.M. Tsatsakis, G.N. Tzanakakis, & M.P. Mingeot-Leclercq. 2006. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J. Antimicrob. Chemother. 57:236-244

3.611

37 Vandevuer S., F. Van Bambeke, P.M. Tulkens & M. Prévost. 2006. Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying cross-linking data: insight into the mechanism of ligand migration and binding sites. Proteins (Proteins-structure function and bioinformatics) , 63:466-478

4.429

38 Servais H. , Y. Jossin, F. Van Bambeke, P.M. Tulkens & M.P. Mingeot-Leclercq. 2006. Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob Agents Chemother. 50:1213-1221

4.246

39 Barcia-Macay M., C. Seral, M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activity of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother., 50:841-851

4.246

40 Michot, J.M, M.F. Heremans, N.E. Caceres, M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke. 2006. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob Agents Chemother., 50:1689-1695

4.246

41 Barcia-Macay M., M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke. 2006. Evaluation of the Extracellular and Intracellular Activities (human THP-1 macrophages) of Telavancin vs. Vancomycin against Methicillin-susceptible, Methicillin-resistant, Vancomycin-intermediate and Vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother 58:1177–1184

3.886

42 P. Baudoux, N. Bles, S. Lemaire, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke.2007. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J.

3.886


Antimicrob. Chemother 59:246-53

43 N. Mesaros, Y.Glupczynski, L. Avrain, N.E. Caceres, P.M. Tulkens, F.Van Bambeke. 2007. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J. Antimicrob. Chemother 59:378-386

3.886

44 Lemaire S., F. Van Bambeke, Y. Glupczynski, P.M. Tulkens. 2007. Intraphagocytic Methicillin-Resistant Staphylococcus aureus are susceptible to Meropenem and Cloxacillin: role of acid pH. Antimicrob Agents Chemother. 51:1627-1632

4.246

45 Lemaire S., F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens. 2007. Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) Efflux Transporter in human THP-1 macrophages and Madin-Darby canine kidney cells. Antimicrob Agents Chemother. 51:2748-2757

4.379

46 Mathot F., A. Schanck, F. Van Bambeke, A. Ariën, M. Noppe , M. Brewster , V. Préat. 2007. Passive diffusion of polymeric surfactants across lipid bilayers. J. Control. Release 120:79-87

4.012

47 Avrain L., M. Garvey, N. Mesaros, Y. Glupczynski, M.P. Mingeot-Leclercq,L.J.V. Piddock, P.M. Tulkens, R. Vanhoof , F. Van Bambeke. 2007. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to sub-inhibitory drug concentrations. J. Antimicrob. Chemother 60:965-972

3.891

48 Barcia-Macay M., M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke. 2008. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages; rat embryonic fibroblasts). J. Antimicrob. Chemother 61:1288-1294

3.891

49 S. Lemaire, C. Fuda, F. Van Bambeke, P.M. Tulkens & S. Mobashery. 2008. Restoration of susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics by acidic pH: role of penicillin-binding-protein 2A (PBP 2A). J. Biol. Chem. 283:12769-12776

5.808

50 H. Bensikaddour H, K. Snoussi, L. Lins, R. Brasseur, F. Van Bambeke, P.M. Tulkens, E. Goormaghtigh, M.P. Mingeot-Leclercq. 2008. Interactions of ciprofloxacin with DPPC and DPPG: Fluorescence anisotropy, ATR-FTIR and 31P NMR spectroscopies and conformational analysis. Biochim. Biophys. Acta (Biomembranes) 1778:2535-2543

3.640

51 S. Lemaire, K. Kosowska-Shick, K. Julian, P.M. Tulkens, F. Van Bambeke, P.C. Appelbaum. 2008. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of S. aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin. Microbiol. Infect. 14:766-777

2.980

52 S. Denamur, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens. 2008. Apoptosis induced by aminoglycosides in LLC-PK1 cells: comparison between neomycin, gentamicin, amikacin, and isepamicin using electroporation. Antimicrob. Ag. Chemother 52:2236–2238

4.390

53 S. Lemaire S, A. Olivier, F. Van Bambeke, P.M. Tulkens, P.C. Appelbaum, Y. Glupczynski. 2008. Restoration of susceptibility of intracellular Methicillin Resistant Staphylococcus aureus (MRSA) to beta-lactams: comparison between strains, cells, and antibiotics. Antimicrob. Ag. Chemother 52:2997-2805

4.390

54 A. Lismond, P.M.Tulkens, M.P. Mingeot-Leclercq, P.Courvalin, F. Van Bambeke. 2008. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes. Studies with ciprofloxacin and moxifloxacin. Antimicrob. Ag. Chemother 52:3040-3046

4.390

55 S. Van de Velde , H.A. Nguyen, F. Van Bambeke, P.M. Tulkens, J. Grellet, V. Dubois, C. Quentin, M.C. Saux. 2008. Contrasting effects of human THP-1 cells differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes. J. Antimicrob. Chemother 62:518-521

4.038

56 H.A. Nguyen HA, O. Denis, A. Vergison, A. Theunis, P.M. Tulkens, M.J. Struelens, F. Van Bambeke. 2009. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus Small Colony Variant isolated from a cystic fibrosis patient : Pharmacodynamic evaluation and comparison with isogenic normal phenotype and revertant

4.717


strains. Antimicrob. Ag. Chemother. 53:1434–1442

57 H.A. Nguyen HA, O. Denis, A. Vergison, P.M. Tulkens, M.J. Struelens, F. Van Bambeke. 2009. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus Small Colony Variant isolated from a cystic fibrosis patient : Study of antibiotic combinations. Antimicrob. Ag. Chemother. 53: 1443-1449

4.717

58 J.P. Becker, G. Depret, F. Van Bambeke, P.M. Tulkens, M. Prevost. 2009. Molecular models of human P-glycoprotein in two different catalytic states. BMC Structural Biology 9:3

3.060

59 S. Lemaire, Y. Glupczynski, V. Duval, B. Joris, P.M. Tulkens, F. Van Bambeke. 2009. Activity of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages, keratinocytes) forms of Methicillin-Sensitive (MSSA) and Methicillin-Resistant Staphylococcus aureus (MRSA). Antimicrob. Ag. Chemother. 53: 2289-2297

4.717

60 B. Marquez, N.E. Caceres, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke. 2009. Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob. Ag. Chemother. 53: 2410-2416

4.390

61 Olivier AC, Lemaire S, Van Bambeke F, Tulkens PM, Oldfield E. 2009. Role of rsbU and staphyloxanthin in phagocytosis and intracellular growth of Staphylococcus aureus in human macrophages and endothelial cells. Journal of Infectious Diseases 200:1367-1370

6.035

62 Lemaire S, Van Bambeke F, Tulkens PM. 2009. Cellular accumulation and pharmacodynamic evaluation of the Intracellular activity of CEM-101, a novel fluoroketolide, towards Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrobial Agents and Chemotherapy 53: 3734-3743

4.717

63 Lemaire S, Van Bambeke F, Appelbaum P.C., Tulkens PM. 2009. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. Journal of Antimicrobial Chemotherapy 64:1035-1043

4.238

64 Domenech O, Francius G, Tulkens PM, Van Bambeke F, Dufrene Y, Mingeot-Leclercq MP. 2009. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization. Biochimica et Biophysica Acta - Biomembranes 1788: 1832-1840

4.18

65 Brinch KS, Sandberg A, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Møller N, Høiby N, Kristensen HH. 2009. Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in the mouse peritonitis model. Antimicrobial Agents and Chemotherapy 53: 4801-4808

4.717

66 Franchini C, Muraglia M, Corbo F, Florio MA, Di Mola A, Rosato A, Matucci R, Nesi M, Van Bambeke F, Vitali C. 2009. Synthesis and biological evaluation of 2-mercapto-1,3-benzothiazole derivatives with potential antimicrobial activity. Archiv der Pharmazie - Chemistry in Life Sciences (Weinheim) 342:605-613

1.429

67 Van de Velde S, Delaive E, Dieu M, Carryn S, Van Bambeke F, Devreese B, Raes M, Tulkens PM. 2009. Isolation and 2D-DIGE proteomic analysis of intracellular and extracellular forms of Listeria monocytogenes. Proteomics 9:5484-5496

4.585

68 Tytgat I, Vandevuer S, Ortmans I, Sirockin F, Colacino E, Van Bambeke F, Duez C, Poupaert JH, Tulkens PM, Dejaegere A, Prévost M. 2009. Structure-based design of benzoxazoles as new inhibitors for D-alanyl - D-alanine ligase. QSAR and Combinatorial Sciences 28: 1394-1404

2.594

69 Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Møller N. 2010. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. Journal of Antimicrobial Chemotherapy 65: 962-73

4.238

70 Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Møller N. 2010. Intra- and extracellular activity of dicloxacillin against Staphylococcus aureus in vivo and in vitro. Antimicrobial Agents and Chemotherapy 54:2391-400.

4.717

71 Baudoux P, Lemaire S, Denis O, Tulkens PM, Van Bambeke F, Glupczynski Y. 2010. Activity of quinupristin-dalfopristin against extracellular and intracellular Staphylococcus aureus with various

4.238


resistance phenotypes. Journal of Antimicrobial Chemotherapy 65: 1228-36.

72 Lemaire S, Tulkens PM, Van Bambeke F. 2010. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. Antimicrobial Agents and Chemotherapy 54:2540-8.

4.717

73 Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F. 2010. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and non-phagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrobial Agents and Chemotherapy 54: 2549-59.

4.717

74 Brinch KS, Tulkens PM, Van Bambeke F, Frimodt-Møller N, Høiby N, Kristensen HH. 2010. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. Journal of Antimicrobial Chemotherapy 65:1720-1724.

4.238

75 Becker JP, Van Bambeke F, Tulkens PM, Prévost M. 2010. Dynamics and structural changes induced by ATP binding in SAV1866, a bacterial ABC exporter. Journal of Physical Chemistry B 114:15948-15957

4.189

76 Domenech O, Dufrêne Y, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP. 2010. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochimica et Biophysica Acta - Biomembranes 1798:1876-1885

3.998

77 El Garch F, Lismond A, Piddock LJV, Courvalin P, Tulkens PM, Van Bambeke F. 2010. Fluoroquinolones induce the expression of patA and patB which encode ABC efflux pumps in Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 65:2076-82

4.352

78 Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Pierard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y. 2010. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. International Journal of Antimicrobial Agents 36:513-522

3.032

79 Lemaire S, Kosowska-Shick K, Appelbaum PC, Glupczynski Y, Van Bambeke F, Tulkens PM. 2011. Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. Journal of Antimicrobial Chemotherapy 66:596-607

4.352

80 Lemaire S, Tulkens PM, Van Bambeke F. 2011. Contrasting effect of acidic pH on the extracellular and intracellular activity of anti-Gram-positive fluoroquinolones (moxifloxacin and delafloxacin) against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 55:649-58.

4.802

81 Lismond A, Carbonnelle S, Tulkens PM, Van Bambeke F. 2011. Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 66:948-951

4.352

82 Sandberg A, Lemaire S, Van Bambeke F, Tulkens PM, Hughes D, von Eiff C, Frimodt-Møller, N. 2011. Intra- and extracellular activity of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with small-colony variant phenotype in an in vitro (THP-1 macrophages) and an in vivo mouse peritonitis model. Antimicrobial Agents and Chemotherapy 55:1443-1452

4.802

83 Lemaire S, Van Bambeke F, Pierard D, Appelbaum PC, Tulkens PM. 2011. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clinical Infectious Diseases 52 Suppl 7:S493-503

8.195

84 Denamur S, Tyteca D, Marchand-Brynaert J, Van Bambeke F, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. 2011. Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. Free Radical Biology & Medicine 51:1656-1665

5.701

85 Lemaire S, Kosowska-Shick K, Appelbaum PC, Glupczynski Y, Van Bambeke F, Tulkens PM. 2011. Activity of moxifloxacin against intracellular community-acquired methicillin-resistant

4.659


Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. Journal of Antimicrobial Chemotherapy 66:596-607

86 Lemaire S, Van Bambeke F, Tulkens PM. 2011. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila. International Journal of Antimicrobial Agents 38:52-59.

3.787

87 Marquez B, Ameye G, Vallet CM, Tulkens PM, Poirel HA, Van Bambeke F. 2011. Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin. PLoS ONE (Public Library of Science) 6:e28368

4.411

88 Sandberg A, Lemaire S, Van Bambeke F, Tulkens PM, Hughes D, von Eiff C, Frimodt-Møller, N. 2011. Intra- and extracellular activity of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with small-colony variant phenotype in an in vitro (THP-1 macrophages) and an in vivo mouse peritonitis model. Antimicrobial Agents and Chemotherapy 55:1443-1452

4.672

89 Vallet CM, Marquez B, Ngabirano E, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2011. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin, and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. International Journal of Antimicrobial Agents 38:249-256.

3.787

90 Vallet CM, Marquez B, Nhiri N, Anantharajah A, Mingeot-Leclercq M-P, Tulkens PM, Lallemand J-Y, Jacquet E, Van Bambeke F. 2011. Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. Toxicology 290:179-187

3.650

91 Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B. 2012. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clinical Infectious Diseases 54 (Suppl 3) S229-S232

9.154

92 Buyck JM, Guénard S, Plésiat P, Tulkens PM, Van Bambeke F. 2012. Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. Journal of Antimicrobial Chemotherapy 67:771-775.

5.068

93 Buyck JM, Plésiat P, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F. 2012. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids (serum, bronchoalveolar lavage) by decreased expression of OprM (efflux impairment) and increased outer membrane permeability. Clinical Infectious Diseases 55:534-542

9.154

94 Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, Tulkens PM, Van Bambeke F. 2012. Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Antimicrobial Agents and Chemotherapy 56:3700-3711

4.851

95 Garcia LG, Lemaire S, Kahl B, Becker L, Proctor R, Tulkens PM, Van Bambeke F. 2012. Influence of the protein kinase C activator, phorbol myristate acetate (PMA), on the intracellular activity of antibiotics against hemin and menadione auxotrophic Small-Colony Variant (SCV) mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells. Antimicrobial Agents and Chemotherapy 56:6166-6174

4.851

96 Garcia LG, Lemaire S, Kahl B, Becker K, Proctor RA, Tulkens PM, Van Bambeke F. 2012. Intracellular forms of menadione-dependent Small-Colony Variants of methicillin-resistant Staphylococcus aureus are hypersusceptible to beta-lactams in a model of THP-1 cells due to cooperation between vacuolar acidic pH and oxidant species. Journal of Antimicrobial Chemotherapy 67:2873-2881

5.068

97 Imbuluzqueta E, Lemaire S, Gamazo C, Elizondo E, Ventosa N, Veciana J, Van Bambeke F, Blanco-Prieto MJ. 2012. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated

5.068


gentamicin. Journal of Antimicrobial Chemotherapy 67:2158-2164.

98 Lismond A, Carbonnelle S, Verhaegen J, Schatt P, De Bel A, Jordens P, Jacobs F, Dediste A, Verschuren F, Huang D, Tulkens PM, Glupczynski Y, Van Bambeke F. 2012. Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically-confirmed diagnosis of community-acquired pneumonia (CAP) in Belgium. International Journal of Antimicrobial Agents 39:208– 216

4.128

99 Melard A, Garcia LG, Das D, Rozenberg R, Tulkens PM, Van Bambeke F, Lemaire S. 2013. Activity of ceftaroline against extracellular (broth) and intracellular (THP 1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. Journal of Antimicrobial Chemotherapy 68: 648–658

5.068

100 Caceres NE, Aerts M, Marquez B, Mingeot-Leclercq MP, Tulkens PM, Devreese B, Van Bambeke F. 2013. Analysis of the membrane proteome of ciprofloxacin-resistant macrophages by stable isotope labeling with amino acids in cell culture (SILAC). PloS one - 8(3):e58285

4.092

101 Buyck JM, Tulkens PM, Van Bambeke F. 2013. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrobial Agents and Chemotherapy – 57:2310-2318

4.851

102 Bauer J, Siala W, Tulkens PM, Van Bambeke F. 2013. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrobial Agents and Chemotherapy – 57:2726-37

4.851

103 Catalano A, Carocci A, Defrenza I, Muraglia M, Carrieri C, Van Bambeke F, Filomena Corbo A, Franchini C. 2013. 2-Aminobenzothiazole derivatives: Search for new antifungal agents. European Journal of Medicinal Chemistry 64C:357-364

3.499

104 B. Marquez, V. Pourcelle, C.M. Vallet, M.-P. Mingeot-Leclercq, P.M. Tulkens, J. Marchand-Bruynaert, F. Van Bambeke. 2013. Pharmacological characterization of 7-(4-(piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity. Pharmaceutical Research. In the press

4.742

International review papers

1 Mingeot-Leclercq, M.P., A. Schanck, F. Van Bambeke, P.M. Tulkens, L. Lins & R. Brasseur. 1995. Molecular description of the interactions of aminoglycoside antibiotics with negatively-charged phospholipids. Theoretical molecular modelling and experimental results. Life Sciences Advances (Pharmacology) 14, 71-98.

1.148

2 Van Bambeke, F., E. Balzi & P.M. Tulkens. 2000. Antibiotic efflux pumps (commentary). Biochem. Pharmacol. 60, 457-470

2.755

3 Van Bambeke F. & P.M.Tulkens. 2001. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 18 Suppl 1:17-23.

1.141

4 Van Bambeke F., Y. Glupczinsky, P. Plésiat, J.C. Pechère & P.M. Tulkens. 2003. Antibiotic efflux pumps in procaryotic cells: impact for resistance to antibiotic treatments. J. Antimicrob. Chemother. 51:1055-1065.

3.329

5 Van Bambeke F., J.M. Michot & P.M. Tulkens. 2003. Antibiotic efflux pumps in eucaryotic cells: Impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J. Antimicrob. Chemother. 51:1067-1077.

3.329

6 Carryn S., H. Chanteux, C. Seral, M-P Mingeot-Leclercq, F. Van Bambeke, & P.M. Tulkens Intracellular Pharmacodynamics of Antibiotics. 2003. Inf Dis Clin N Am. 17:615-634

1.781

7 Van Bambeke F, Y. Van Laethem, P. Courvalin, & P.M. Tulkens. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Pharmacological properties and clinical use. Drugs. 64:913-936.

5.368

8 Van Bambeke F. 2004. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol. 4:471-478.

4.593


9 Van Bambeke, F., J.M. Michot, J. Van Eldere, and P.M. Tulkens. 2005. Quinolones in 2005: an update. Clin. Microbiol. Infect., 11:256-280.

2.238

10 Van Bambeke, F. J.M. Pagès, & V.J. Lee. 2006. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Patents On AntiInfective Drug Discovery, 1:157-175

new journal

11 Van Bambeke F., M. Barcia-Macay, S. Lemaire & P.M. Tulkens. 2006. Cellular pharmacokinetics and pharmacodynamics of antibiotics: current views and perspectives. Current Opinion in Drug Discovery & Development, 9:218-230

3.698

12 Van Bambeke, F. 2006. Glycopeptides and glycodepsipeptides in clinical developement: a comparative of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Cu. Op. Invest.Drugs, 7:740-749

new journal

13 Mesaros N., P. Nordmann, P. Plésiat, M. Roussel-Delvallez, J. Van Eldere, Y. Glupczynski, Y. Van Laethem, F. Jacobs, P. Lebecque, A. Malfroot, P.M. Tulkens, F. Van Bambeke. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin.Microbiol. Infect 13: 560–578.

2.679

14 Van Bambeke F., R.R. Reinert, P.C. Appelbaum, P.M. Tulkens, W.E. Peetermans. 2007. Multidrug-Resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 67:2355-2382

4.472

15 Van Bambeke F., J. Harms, Y. Van Laethem , P.M. Tulkens. 2008. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Exp. Op. Pharmacother. 9:267-283

1.733

16 Van Bambeke F., M.P. Mingeot-Leclercq, M.J. Struelens, P.M. Tulkens. 2008. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol. Sci. 29:124-134.

10.40

17 Van Bambeke F, P.M. Tulkens. 2009. Safety profile of moxifloxacin, a respiratory fluoroquinolone: comparison with other fluoroquinolones and other antibiotic classes. Drug Saf. 32:359-378

3.597

18 Tytgat I., E. Colacino, P.M. Tulkens,J.H. Poupaert, M. Prévost, F. Van Bambeke. 2009. DD- ligases as a potential target for antibiotics: past, present and future. Cur. Med. Chem. 16: 2566-2580

4.944

19 Van Bambeke F. 2011. ABC transporters: role in modulation of drug pharmacokinetics and in physiopathology and therapeutic perspectives (Editorial). Curr Drug Targets. 12:598-599

4.187

20 Marquez B and F. Van Bambeke. 2011. ABC multidrug transporters: Target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets. 12:600-620

4.187

21 Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, Tulkens PM, Van Bambeke F. 2013. Antibiotic activity against Small Colony Variants of Staphylococcus aureus: Review of in vitro, animal, and clinical data. Journal of Antimicrobial Chemotherapy 68:1455-1464

5.338

Book chapters - Van Bambeke, F., D.M. Lambert, M.P. Mingeot-Leclercq & P.M. Tulkens. 1999. Anti-

infective therapy: Mechanisms of action. In: Infectious Diseases (D. Armstrong & J. Cohen, Eds), Mosby, London, United Kingdom. Section 7, 1.1-1.14. (deuxième édition parue en 2003; 3eme édition en 2010) – ISBN 978-0-323-04579-7

- Van Bambeke, F. & P.M. Tulkens. 2002. Médicaments anti-infectieux dans le traitement des

infections du système nerveux central. in: neuroinfectiologie (C. Sindik, Ed), Doin, France. chap 20. 355-388.

- Mulazimoglu, L, P. M. Tulkens & F. Van Bambeke. 2005. Macrolides. In: Anti-infective

therapy, Serie Antimicrobial therapy and vaccines ((Yu,V.L.; Edwards,G.; McKinnon,P.S.;


Peloquin,C.; Morse,G.D.ed.). Esun Technologies, Pittsburgh, PA, 243-280. – ISBN 0-9744641-1-2.

- Van Bambeke F, Virgincar N, MacGowan A. Update 2009. Glycopeptides (Dalbavancin,

Oritavancin, Teicoplanin, Telavancin, Vancomycin) - Antimicrobial Therapy and Vaccines. Vol. II: Antimicrobial Agents (2009) 42pp V.L. Yu et al. Eds; Web edition (Esun Technologies), Pittsburgh, PA - – ISBN 0-9744641-1-2

- Lemaire S, Tulkens PM, Van Bambeke F. 2009. Therapeutic options for intracellular MRSA:

Current views and perspectives. In: Methicillin-Resistant Staphylococcus Aureus (MRSA): Etiology, At-Risk Populations and Treatment (C.L. Kolendi, ed.), chapter 2, pp 55-74 - 978-1-60741-398-1

- Van Bambeke F, Pagès J-M, Lee VJ. 2010. Inhibitors of bacterial efflux pumps as adjuvants

in antibacterial therapy and diagnostic tools for detection of resistance by efflux. In: Frontiers in Anti-Infective Drug Discovery (2010) vol. 1, 138-175, Atta-ur-Rahman & M. Iqbal Choudhary (Eds.), Bentham Science Publishers. - ISSN: 1877-3818

- Van Bambeke F. 2010. Erythromycin. In: Kucers's the use of antibiotics: a clinical review of

antibacterial, antifungal, antiparasitic and antiviral drugs. 6th Edition, volume 1, pages 751-769, Edward Arnold (Publishers) Ltd. ISBN: 9780340927670

- Van Bambeke F. 2010. Roxithromycin. In: Kucers's the use of antibiotics: a clinical review of

antibacterial, antifungal, antiparasitic and antiviral drugs, 6th Edition, volume 1, pages 770-778, Edward Arnold (Publishers) Ltd. ISBN: 9780340927670

- Van Bambeke F. 2010. Josamycin and rosaramicin. In: Kucers's the use of antibiotics: a

clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs 6th Edition, volume 1, pages 819-824, Edward Arnold (Publishers) Ltd. ISBN: 9780340927670

- Gordon C, Van Bambeke F. 2010. Azithromycin. In: Kucers's the use of antibiotics: a clinical

review of antibacterial, antifungal, antiparasitic and antiviral drugs. 6th Edition, volume 1, pages 801-818, Edward Arnold (Publishers) Ltd. ISBN: 9780340927670

- Langan C, Van Bambeke F. 2010. Clarithromycin. In: Kucers's the use of antibiotics: a

clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. 6th Edition, volume 1, pages 779-800, Edward Arnold (Publishers) Ltd. ISBN: 9780340927670

- Van Bambeke F. 2014. Macrolides and Ketolides. In: Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. Springer Science ed. In the press.

Educational papers - Van Bambeke, F. and P.M. Tulkens. Pharmacologie et pharmacothérapie anti-infectieuse.

Antibiotiques, antiviraux et antifongiques. In Syllabus National de Pharmacologie (coordinateur, Prof. A. Herschuelz). 1999. 238 pp.

- Van Bambeke, F., J. Nachega & P.M. Tulkens. 1996. Traitement des infections à Herpes

simplex, Varicella zoster et cytomegalovirus. Louvain Méd. 115, 735-744.


- J. Nachega, F. Van Bambeke, B. Vandercam & P.M. Tulkens. 1997. Usages cliniques actuels et raisonnables des glycopeptides. Louvain Méd. 116 162-174.

- Van Bambeke F., G. Bigaignon, J. Ninane & P.M. Tulkens. 1998. La maladie de Lyme:

diagnostic et thérapeutique rationnels. Louvain Méd. 117, 375-388. - Van Bambeke, F., D. Tyteca, Y. Ouadrhiri & P.M. Tulkens. 1999. Optimisation des

traitements antibactériens sur base des propriétés pharmacodynamiques des antibiotiques. Louvain Med. 118, 43-63.

- Van Bambeke F. & P.M. Tulkens. 1999. Optimisation des traitements antibactériens sur

base de propriétés pharmacodynamiques des antibiotiques. Medisphère 93, 21-24. - Van Bambeke F. & P. Courvalin. 2000. Coût biologique de la résistance aux antibiotiques:

Vancomycine-dépendance, le prix ultime bactérien ? La Lettre de l'Infectiologue 15, 285-294. - Van Bambeke F., J. Verhaegen, D. Tyteca, R. Auckenthaler & P.M. Tulkens. 2000.

Erythromycine et néomacrolides actuels, usages cliniques et perspectives. Louvain Méd. 119, 259-286.

- Van Bambeke F., J. Verhaegen, D. Tyteca, R. Auckenthaler & P.M. Tulkens.2001.

Erytromycine en huidige neomacroliden: klinish gebruik en perspectieven. Tijdschrift voor geneeskunde 57, 382-395.

- Van Bambeke F., J. Verhaegen, D. Tyteca, R. Auckenthaler & P.M. Tulkens. 2001.

Erythromycine et néomacrolides actuels, usages cliniques et perspectives. Med Hyg 59, 2316-2323.

- Van Bambeke F., J. Verhaegen, & P.M. Tulkens. 2001. Erythromycine, autres macrolides et

kétolides: usages cliniques actuels et perspectives. La lettre de l'infectiologue XVI: 318-331 - Mesaros, N., F. Van Bambeke, Y. Glupczynski, R. Vanhoof & P.M. Tulkens. 2005. L’efflux

des antibiotiques: un mécanisme ubiquitaire conduisant à la résistance. Etat de la question et implications microbiologiques et cliniques. Louvain Méd., 124:308-3202.

- N. Mesaros, F. Van Bambeke, L. Avrain, Y. Glupczynski , R. Vanhoof , P. Plesiat, PM.

Tulkens. 2005. L'efflux actif des antibiotiques et la résistance bactérienne: état de la question et implications. La Lettre de l'Infectiologue 20:117-1263.

- N. Mesaros, F. Van Bambeke, L. Avrain, G. Glupczynski, R. Vanhoof, P.M. Tulkens. 2005.

Actieve efflux van antibiotica en bacteriële resistentie: stand van zake en implicaties. Tijdschrift voor Geneeskunde 61:1407-1417.

- N. Mesaros, P. Nordmann, P. Plésiat, M. Roussel-Delvallez, J. Van Eldere, Y. Glupczynski,

Y. Van Laethem, F. Jacobs, P. Lebecque, A. Malfroot, P.M. Tulkens, F. Van Bambeke. 2007. Pseudomonas aeruginosa: resistance et options thérapeutiques à l'aube du deuxième millénaire. Louvain Méd., 126: 305-316.

- F. Van Bambeke. 2008. L'ABC des hépatites virales. J. Pharm. Belg. 63:15-20


- F. Van Bambeke & P.M. Tulkens. 2009. Pharmacodynamie des antibiotiques dans le liquide céphalo-rachidien (LCR): principes et conséquences (facteurs prédictifs d'efficacité). Med. Mal. Infect. (2009) 39:483-492

- L. Avrain, P. Mertens, F. Van Bambeke. 2013. RND efflux pumps in P. aeruginosa: an underestimated resistance mechanism. Clinical Laboratory International [Cli-online] April-May 26-28


Abstracts (national meetings; *: presenting author):

- Van Bambeke, F.*, M.P. Mingeot-Leclercq* & P.M. Tulkens. 1993. Alterations in membrane permeability induced by

aminoglycoside antibiotics. Studies on liposomes and cells. Arch. Int. Physiol. Biochim. Biophys. 101:B21. - Mingeot-Leclercq, M.P.*, L. Depienne, F. Van Bambeke*, J.P. Montenez & P.M. Tulkens. 1994. Interaction of

aminoglycoside and macrolide antibiotics with membranes. Effect on Ca2+ permeability. Cell Biol. Int. Rep. 17/2. - Van Bambeke, F*., M.P. Mingeot-Leclercq*, L. Depienne & P.M. Tulkens. 1994. Evaluation of the capacity of

aminoglycoside antibiotics to induce aggregation or fusion of liposomes, measured by the dequenching of the fluorescence of octadecylrhodamine B chloride (R18). Cell Biol. Int. Rep. 17/2.

- Van Bambeke, F*., M.P. Mingeot-Leclercq*, A. Schanck, R. Brasseur & P. Tulkens. 1994. Aminoglycoside antibiotics induced alterations in membrane permeability of liposomes to increasing molecular weight markers. Cell Biol. Int. Rep. 17/2.

- Tyteca, D*., L. Belaabidia*, J.P. Montenez, F. Van Bambeke*, M.P. Mingeot-Leclercq, J. Piret, R. Brasseur & P.M.

Tulkens. 1996. In vitro comparative studies of the interactions of gentamicin and azithromycin with membrane lipids: contribution to the understanding of the molecular mechanism by which they cause a lysosomal phospholipidosis in cultured cells. Arch. Physiol. Biochem. 104:B22.

- Michot, J.M.*, F. Van Bambeke*, C. Gerbaux, J.P. Montenez & P.M. Tulkens. 1997. Influence of low doses of

azithromycin on lysosomal metabolism in cultured rat embyo fibroblats. Arch. Physiol. Biochem. 105:B11. - Kerkhofs, A.*, F. Van Bambeke, E. Sonveaux, P.M. Tulkens & M.P. Mingeot-Leclercq. 1997. pH-sensitivity, leakage

efficiency and endocytosis pathway of pH-sensitive liposomes DOPE/CHEMS AND DOPE/OA. In 7th Forum of pharmaceutical sciences, Blankenberg, Belgium.

- J.M. Michot*, A. Decottignies, P.M. Tulkens & F. Van Bambeke*.1998. In search of efflux pumps to fluoroquinolones

in macrophages. In 11th Meeting of the Belgian Society for Infectiology and Clinic microbiology, Gent, Belgium. - Tyteca, D.*, F. Van Bambeke*, P.M. Tulkens & M.P. Mingeot-Leclercq. 1998. Perturbation of membrane traffic

induced in cultured cells by azithromycin, a lysosomotropic antibiotic. Arch. Int. Physiol. Biochim. Biophys. - Uwamahoro, M.J., S. Carryn, J.M. Michot, M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke*. 2000.

Modulation of the cellular accumulation of ciprofloxacin and moxifloxacin in J774 macrophages. In 15th Symposium (fall 2000) of the Belgian Society for Infectiology and Clinical microbiology, Brussels, Belgium.

- S. Carryn*, Y. Ouadrhiri, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens. 2000. Pharmacodynamics of two -lactams and two fluoroquinolones against extracellular and intracellular Listeria monocytogenes . In 15th Symposium (fall 2000) of the Belgian Society for Infectiology and Clinical microbiology, Brussels, Belgium.

- M. Barcia-Macay, S. Carryn, S. Lemaire, C. Seral, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke. 2004.

Intracellular models of infection to evaluate antibiotic activity. In Annual meeting of the Belgian Society for Microbiology, Brussels, Belgium.

- G. Depret, J.-P. Becker, P.M. Tulkens, F. Van Bambeke, and M. Prévost. 2007. Modeling of a transmembrane

multidrug resistance protein, P-glycoprotein. Joint meeting of the Belgian FNRS contact group "Proteomics" and the Belgian Society of Biochemistry and Molecular Biology "Organelle sub-proteomics and post-translationals modifications", Brussels, Belgium.

- J. Buyck, O. Jolois, P.M. Tulkens and F. Van Bambeke. 2010. Setting-up a model of intracellular infection by

Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. BioWin Day - Science for Business : Open innovation, the new model to innovate in health. Louvain-La-Neuve, Belgium.

Abstracts (international meetings; *: presenting author): see: http://www.facm.ucl.ac.be/posters.htm for the corresponding pdfs 1. 11th International Biophysics Congress, Budapest, Hungary, 1993.

- Mingeot-Leclercq, M.P.*, F. Van Bambeke*, R. Brasseur & P.M. Tulkens. Aminoglycoside-induced increase in membrane permeability. II. Studies with cultured cells. Abstract n°C5.32.

- Van Bambeke, F.*, M.P. Mingeot-Leclercq*, L. Depienne, A. Schanck & P.M. Tulkens.. Aminoglycoside-induced increase in membrane permeability. I. Studies with large unilamellar vesicles. Abstract n°C5.31.

2. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993

- Van Bambeke, F*., M.P. Mingeot-Leclercq, L. Depienne & P.M. Tulkens. 1993. Aminoglycoside induced increase of membrane permeability in liposomes and cultured cells. Abstract n°218B.

3. FEBS Special Meeting Biological Membranes, Helsinki, Finland, 1994

- Mingeot-Leclercq, M.P.*, F. Van Bambeke*, A. Schanck, L. Depienne, J.P. Montenez & P.M. Tulkens. Effect of aminoglycoside and macrolide antibiotics on membrane permeabilityAbstract n°248.


- Van Bambeke, F*., M.P. Mingeot-Leclercq,* L. Depienne & P.M. Tulkens. Evaluation of aminoglycoside antibiotics capacity to induce aggregation or fusion of liposomes, by using 3 complementary fluorescence techniques. Abstract n°247.

4. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.

- Van Bambeke, F.*, M.P. Mingeot-Leclercq, L. Depienne & P.M. Tulkens. Aminoglycosides induce aggregation but not fusion of liposomes, as evidenced by biophysical and morphological approaches. Abstract n°A108a.

5. Comptes-rendus du GERM XIV, Anglet-Biarritz, France.1995.

- Schanck, A.*, F. Van Bambeke, P.M. Tulkens & M.P. Mingeot-Leclercq. 31P NMR of negatively-charged liposomes interacting with aminoglycosides. Abstract n°60.

6. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. 1995.

- Van Bambeke, F.*, M.P. Mingeot-Leclercq, A. Schanck, R. Brasseur & P.M. Tulkens. Aminoglycosides aggregate membranes and prevent phospholipid reorganization: comparative studies with gentamicin, amikacin, and isepamicin and correlation with nephrotoxicity. Abstract n°913.

7. 19th Intern. Congress of Chemotherapy, Montreal, Quebec, Canada. 1995.

- Van Bambeke, F.*, P.M. Tulkens, A. Schanck & M.P. Mingeot-Leclercq. Aminoglycoside antibiotics cause aggregation of negatively-charged membranes but inhibit the lipid reorganization necessary for their fusion. In. J. Infect. Dis. 6 suppl. C. Abstract n°3009.

8. Satellite symposium on pharmacodynamics of antimicrobials, International Society of Antinfective Pharmacology, Québec, Québec, Canada. 1995.

- Van Bambeke, F*., P.M. Tulkens, A. Schanck & M.P. Mingeot-Leclercq. Deciphering the toxicological parameters of aminoglycoside nephrotoxicity: a combined biophysical and biochemical study of gentamicin, amikacin and isepamicin in interaction with phosphatidylinositol-containing lipid vesicles. Abstract n°27.

8. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA.1996.

- Gerbaux, C., F. Van Bambeke*, J. Piret, G. Morlighem & P.M. Tulkens. Paradoxical increase of the activities of lysosomal enzymes in lysates of rat embryo fibroblasts incubated with azithromycin. In Abstract n°A84.

- Montenez, J.P., F. Van Bambeke*, M.P. Mingeot-Leclercq, J. Piret, R. Brasseur & P.M. Tulkens. Azithromycin causes an accumulation of lipids in lysosomes of cultured cells: Biochemical mechanism and potential relationship with its long-time retention in cells. Abstract n°A85.

9. Liposome Advances (Progress in drug and vaccine delivery), London, England. 1996.

- Kerkhofs, A.*, F. Van Bambeke, E. Sonveaux, P.M. Tulkens & M.P. Mingeot-Leclercq. pH-sensitive liposomes: pH-sensitivity, leakage efficiency, endocytosis, and natural targeting to the acidic compartments. Abstract n°A 42.

10. 24th Meeting of the Federation of European Biochemical Societies, Barcelona, Spain. 1996.

- Mingeot-Leclercq, M.P.*, J.P. Montenez, F. Van Bambeke*, A. Schanck, R. Brasseur & P.M. Tulkens. Interaction of cationic lysosomotropic antibiotics with negatively-charged membranes. II. Molecular characterization by biophysical and computer-aided conformational studies. PS23-48.

- Van Bambeke, F.*, J.P. Montenez, M.P. Mingeot-Leclerq*, L. Belaabidia, D. Tyteca & P.M. Tulkens. Interaction of cationic lysosomotropic antibiotics with negatively-charged membranes. I. Binding, inhibition of lysosomal phospholipase A1 and influence on bilayer aggregation/fusion. PS23-47.

11. Page-Wood International Symposium on Membrane Traffic in Health and Disease, Cleveland, Ohio. 1997.

- Van Bambeke, F.*, J.P. Montenez, M.P. Mingeot-Leclercq, J. Nachega, P.J. Courtoy & P.M. Tulkens. Perturbation of endosome-lysosome fusion induced in cultured cells by two lysosomotropic antibiotics (azithromycin, gentamicin) causing a lysosomal phospholipidosis. Abstract n°42.

12. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. 1997.

- Montenez, J.P., F. Van Bambeke*, J. Piret, R. Brasseur, P.M. Tulkens & M.P. Mingeot-Leclercq. Comparative studies of lysosomal phospholipidosis induced by four macrolides. Abstract n°F266.

13. Satellite symposium on pharmacodynamics of antimicrobials, International Society of Antinfective

Pharmacology, San Diego, CA. 1998. - Tyteca, D., F. Van Bambeke*, P.M. Tulkens & M.P. Mingeot-Leclercq. Perturbation of endocytosis induced by

azithromycin in a model of cultured cells. 14. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.

- Michot, J.M., C. Gerbaux, F. Van Bambeke*, M. Bouvier d'Yvoire & P.M. Tulkens. Lysosomal alterations induced in cultured cells models by long-term exposure to low, clinically meaningful concentrations of azithromycin. I052.

- Van Bambeke, F.,* M. Chauvel, P.E. Reynolds, H.S. Fraimow & P. Courvalin. Study of vancomycin-dependent (VmD) Enterococcus faecalis clinical isolates and of in vitro revertant mutants. C086.


15. European Congress of Cell Biology, Bologna, Italy. D-147. 1999. - Tyteca, D*., F. Van Bambeke, P.M. Tulkens & M.P. Mingeot-Leclercq. Azithromycin, a lysosomotropic

antibiotic, perturbs the early stages of endocytosis in phagocytic and non-phagocytic cells. 16. 2000 Years of Natural Products Research - Past, Present and Future, Amsterdam, The Netherlands. 1999

- Quetin-Leclercq, J.*, G. Schomer, F. Van Bambeke, M.-Cl. De Pauw-Gillet, M. Frederich, M. Tits, L. Angenot & M.-P. Mingeot-Leclercq. Lysosomal phospholipases inhibition by emetine, strychnopentamine and usambarensine.

17. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. 1999.

- Prévost, M., D. Van Belle, P.M. Tulkens, P. Courvalin & F. Van Bambeke*. Structure and function of Enterococcus faecalis D-Alanyl:D-Alanine ligase by comparative computer-aided conformational analysis. 1139.

- Y. Gholizadeh, F. Van Bambeke*, M. Prévost, H.S. Fraimow, E. Chachaty, L.L. Dever, P.M. Tulkens, & P. Courvalin. Study of Glycopeptide-Dependent Enterococcus faecium clinical isolates by sequencing of the ddl gene and computer-aided modeling of the mutated d-Ala:D-Ala ligase. 1447.

- Tyteca, D., F. Van Bambeke,* P.M. Tulkens & M.P. Mingeot-Leclercq. Macrolide antibiotics (azithromycin and erythromycylamine) perturb the early stages of endocytosis in phagocytic and non-phagocytoc cells. 1756.

- Gerbaux-Morlighem, C., F. Van Bambeke* & P.M. Tulkens. Azithromycin increases the activity of cathepsin B, a lysosomal endopeptidase, by inhibiting its degradation in rat embryo fibroblasts. 1757.

18. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. 2000.

- Uwamahoro, M.J., S. Carryn, J.M. Michot, M.P. Mingeot-Leclercq, P.M. Tulkens & F. Van Bambeke*. Modulation of the cellular accumulation of ciprofloxacin and moxifloxacin in J774 macrophages. 2268.

- Michot, J.M*., F. Van Bambeke, M.P. Mingeot-Leclercq & P.M. Tulkens. Identification and characterization of ciprofloxacin efflux transporter in murine J774 macrophages. 662.

19. 41st International Conference on the Biochemistry of Lipids, Haale (Saale), Germany. 2000.

- Tyteca, D.*, F. Van Bambeke, P.M. Tulkens & M.P. Mingeot-Leclercq. Azithromycin, a lysosomotropic antibiotic, impairs endocytosis in cultured macrophages. T3/28.

20. 11th European Congress of Clinical Microbiology and Infectious Diseases, Istambul, Turkey. 2001.

- F. Van Bambeke*, A.-S. Snoeck, H. Chanteux, M.-P. Mingeot-Leclercq & P.M. Tulkens Is LY333328 glycopeptide a new cell-associated antibiotic ? Comparative studies with vancomycin and azithromycin in a model of J774 mouse macrophages.1245

- M.-P. Mingeot-Leclercq* , X. Gallet, F. Van Bambeke, C. Flore, J. Peuvot & R. Brasseur. Experimental and conformational analysis of the interactions between the antifungal butenafine and lipids.. 427

21. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. 2001.

- J. -M. Michot, M.P. Mingeot-Leclercq , F. Van Bambeke*, & P.M. Tulkens. Ciprofloxacin (CIP), but not Moxifloxacin (MXF), is a Substrate of both MRP1 and MDR1 Transporters in Murine J774 Macrophages (MØ). A2208.

- H. Chanteux*, F. Van Bambeke, M.P. Mingeot-Leclercq, E. Sonveaux & P.M. Tulkens. Accumulation of Ester Prodrugs of Ampicillin (AMPI) in J774 Macrophages: Mechanism and Activity Against Intracellular Listeria monocytogenes.. A2070

- F. Van Bambeke*, S. Carryn, A.S. Snoeck, M.P. Mingeot-Leclercq, P.M. Tulkens. LY333328 (Oritavancin) Glycopeptide Accumulates in Cultured Macrophages but is only Bacteriostatic towards Intracellular Listeria monocytogenes. A2069

- S. Carryn*, F. Van Bambeke, M.-P. Mingeot-Leclercq and P. M. Tulkens. Comparative Pharmacodynamics of Ampicillin (AMPI), Meropenem (MERO), Ciprofloxacin (CIP) and Moxifloxacin (MOX) against Extracellular and Intracellular Listeria monocytogenes). A2099.

- 22. 13th European Congress of Clinical Microbiology and Infectious Diseases, Milano, Italy. 2002.

- H. Chanteux*, F. Van Bambeke, M.P. Mingeot-Leclercq, P. M. Tulkens. Cellular accumulation and membrane-binding properties of ester prodrugs of ampicillin (pivaloylampicillin, phthalimidomethylampicillin). P1349.

- C. Seral, J.M. Michot, H. Chanteux, M.P. Mingeot-Leclercq, P. M. Tulkens,* F. Van Bambeke. Inhibitors of P-glycoprotein increase the accumulation of azithromycin and other macrolides in macrophages. P1357.

23. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. 2002.

- F. Van Bambeke*, J. Saffran, M.P. Mingeot-Leclercq and P.M. Tulkens. Oritavancin glycopeptide causes a lipid storage disorder and mixed morphological alterations of the vacuolar system in cultured rat embryo fibroblasts (FB) and J774 mouse macrophages (M). A 508

- C. Seral*, F. Van Bambeke, P. M. Tulkens. Activity of the New Glycopeptide Oritavancin (LY333328; ORI) in a Model of Staphylococcus aureus Intraphagocytic Infection in Comparison with Telithromycin (TEL) and Moxifloxacin (MXF) A483

- C. Seral,* S. Carryn, P. M. Tulkens, F. Van Bambeke. Inhibitors of MDR1 and MRP1 Differently Affect the Accumulation and the Intracellular Activity of Azithromycin (AZM) and Ciprofloxacin (CIP) in J774 Macrophages Infected by Cytosolic (Listeria monocytogenes) or Lysosomal (Staphylococcus aureus) Bacteria. A484

- J. M. Michot*, F. Van Bambeke, M. P. Mingeot-Leclercq, P. M. Tulkens. Development of a Ciprofloxacin-Resistant J774 Macrophage (MØ) Clone [RS] and Characterization of Ciprofloxacin (CIP) and Moxifloxacin (MXF) Accumulation. A486


- H. Chanteux*, F. Van Bambeke, M. Mingeot-Leclercq, E. Sonveaux, P. M. Tulkens. Oriented Transport of Ampicillin Through Caco-2 Intestinal Cells Exposed to Pivaloyl and Phtalimidomethyl Esters of Ampicillin. A487

- H. Chanteux, J. Michot, C. Seral, F. Van Bambeke, M. Mingeot-Leclercq, P. M. Tulken. Ampicillin [AMPI] and Ester Prodrugs of AMPI are not Substrates of MRP and P-gp in J774 MacrophagesA488

- A. Spinewine, F. Van Bambeke,* P. M. Tulkens. A National Website on the Pharmacology and Pharmacotherapy of Antibiotics. W1160.

24. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow (United Kingdom). 2003.

- C. Seral, P.M. Tulkens, * F. Van Bambeke. Modulation of the cellular accumulation of garenoxacin (BMS284756) and levofloxacin in J774 macrophages . P1226

- H. Chanteux*, F. Van Bambeke, M. Mingeot-Leclercq, P. M. Tulkens. Pïvampicillin enhances the activity of ampicillin against intracellular bacteria: studies in a model of J774 macrophages infected with Listeria monocytogenes.. O393.

- S. Carryn*, F. Van Bambeke, M. Mingeot-Leclercq, P. M. Tulkens. GM-CSF limits the intracellular growth of Listeria monocytogenes in THP-1 human macrophages. O153.

- 25. 23rd International Congress of Chemotherapy, Durban (South Africa). 2003.

- F. Van Bambeke,* A.M. Corbisier-Colson, Y. Glupczynski, P.M. Tulkens. Screening of a national fungi collection for the discovery of new antibiotics active against multiresistant strains. MO152.

- C. Seral, F. Van Bambeke,* P.M. Tulkens. Setting – up of a model of S. aureus-infected macrophages for the evaluation of intracellular activity and pharmacodynamic parameters of antibiotics in recurrent infections. SU122.

26. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL .2003

- F. Van Bambeke,* H. Chanteux, D. Tyteca, M.P. Mingeot-Leclercq, P.M. Tulkens. Oritavancin accumulates to high levels in the lysosomes of macrophages by endocytosis. A-1169.

- M . Barcia-Macay, C. Seral, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke . Comparative activity of 12 antibiotics used at clinically-meaningful extracellular concentration against S. aureus in broth and in human THP-1 macrophages. A-1174.

- C. Seral, E. Viaene, F. Van Bambeke,* M.P. Mingeot-Leclercq, P.M. Tulkens. Influence of inhibitors of efflux pumps on the accumulation of quinolones in a model of Calu-3 human airways epithelial cells. A-1175.

- C. Seral, F. Van Bambeke,* P.M. Tulkens. Activity of garenoxacin (BMS284756; GAR) and levofloxacin (LVX) against intracellular Staphylococcus aureus (S.a.) or L. monocytogenes (L.m.) in J774 macrophages. A-1176.

27. Post-ICAAC symposium of the International Society of Antiinfective Pharmacology, Chicago, IL. 2003.

- F. Van Bambeke, S. Carryn, C. Seral, H. Chanteux, D. Tyteca, M.P. Mingeot-Leclercq, P.M. Tulkens . Oritavancin, a new cell associated antibiotic: PK- PD studies in cultured macrophages. oral presentation.

- C. Seral, M. Barcia-Macay, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens. Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection. oral presentation.

28. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic. 2004.

- V. Basma, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens* . Stability and compatibility of temocillin for administration by continuous infusion in intensive care patients. R1919.

- V. Basma, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens*.. Stability and compatibility of vancomycin for administration by continuous infusion in intensive care patients. R1920.

- L. Efron, T. Happaerts, E. Sonveaux, H. Chanteux, Y. Glupszynski, C. Behrin, F.Van Bambeke*, P.M.Tulkens. New penams (6-APA) and cephems (7-ACA) with bulky T-shaped side-chains: synthesis and antibiotic activity. P544.

- S. Lemaire, S. Van de Velde, S. Carryn, F. Van Bambeke,* M.P. Mingeot-Leclercq, P.M. Tulkens.. Comparison of ertapenem, ampicillin, and meropenem against the intracellular forms of Listeria monocytogenes in human THP-1 macrophages. P1045.

- E. Charvalos, M.N. Tzatzarakis, F. Van Bambeke*, P.M. Tulkens,* A.M. Tsatsakis, M.P. Mingeot-Leclercq, In vitro antifungal activity, cytotoxicity, and cellular accumulation of new water soluble amphotericin B (AMB) - polyvinylpyrrolidone (PVP) formulations.. P1785.

29. World Conference on Magic Bullets celebrating Paul Ehrlich’s 150th Birthday, Nurnberg, Germany. 2004.

- M. Barcia-Macay, S. Lemaire, S. Carryn, F. Van Bambeke*, MP Mingeot-Leclercq & PM. Tulkens. Dosing the magic bullets against intracellular bacteria: lessons from a comparison between beta-lactams and quinolones against L. monocytogenes and S. aureus. 652.

- J-M Michot, M. Heremans, F. Van Bambeke,* M-P Mingeot-Leclercq and P. M. Tulkens.. Cellular pharmacokinetics of quinolones revisited : Role of the MDR efflux pumps expressed in macrophages. 651.

30. ISOPOL XV, Uppsala, Sweden. 2004.

- S. Van de Velde* S. Carryn, F. Van Bambeke and P.M. Tulkens. Increased susceptibility of intracellular Listeria monocytogenes to ampicillin studies with Caco-2 cells and THP-1 macrophages. 123


- S. Van de Velde,* S. Carryn, F. Van Bambeke, M-P. Mingeot-Leclercq and P. M. Tulkens. PMA activation increases accumulation and activity against intracellular Listeria monocytogenes in THP-1 cells of ciprofloxacin and moxifloxacin but not of levofloxacin and garenoxacin. 124

31. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. 2004.

- L. Efron, F.Van Bambeke*, C. Behrin, Y. Glupszynski, P.M.Tulkens, E. Sonveaux. Synthesis and activity of Pen G hydroxamic acid derivatives against S. aureus, S. pneumoniae, and intraphagocytic L. monocytogenes. F333.

- M. Heremans, J.M. Michot, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke*. Ciprofloxacin-resistant J774 macrophages show a reduction in the accumulation of quinolones through increased activity of an MRP-like transporter. A1304.

- S. Lemaire, F. Van Bambeke,* M.P. Mingeot-Leclercq, P.M. Tulkens. Contrasting effects of ertapenem against intracellular L. monocytogenes and S. aureus in a model of THP-1 macrophages. A1487.

- H. Servais, E. Delbecq, G. Van der Essen, G. Thirion, F. Van Bambeke, P.M. Tulkens,* M.P. Mingeot-Leclercq. Involvment of mitochondrial pathway and Bax in gentamicin-induced apoptosis in renal LLC-PK1 cells. A1491.

- M . Barcia-Macay, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke*. Beta-lactams are bactericidal against intracellular forms of S. aureus in a 24 h human macrophages model (THP-1 cells). A1488.

32. 24ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse (RICAI) and 6th European Congress of Chemotherapy, Paris, France. 2004.

- N. Mesaros, N. Caceres, F. Van Bambeke, M.P. Mingeot-Leclercq, and P.M. Tulkens*. A versatile method to quantify the expression level of mexAB-oprM AND mexXY-oprM genes in P. aeruginosa. Poster 564/91P

- V. Basma, R. de Jongh, F. Van Bambeke, M.P. Mingeot-Leclercq, and P.M. Tulkens*.Continuous versus intermittent infusion of temocillin in Intensive Care patients. Poster 660/96P

33. The association of biomolecular resource facilities. Savannah, Georgia. 2005.

- N. E. Caceres,* M. P.Mingeot-Leclercq, P.M. Tulkens, R. Wattiez* and F. Van Bambeke. Development of a Protocol for extraction and Preparation of Macrophage Integral Membrane Proteins for Proteomics Analysis by the Conventional 2DE-MS Approach. 05-A54.

34. 7th European Congress of Chemotherapy and Infectious Diseases. Florence, Italy. 2005.

- L. Avrain, N. Mesaros, R. Vanhoof, F. Van Bambeke, and P.M. Tulkens.* Induction of fluoroquinolone efflux in Streptococcus pneumoniae by subinhibitory ciprofloxacin concentrations.. PS2-071

35. 15th European Congress on Clinical Microbiology and Infectious Diseases, Copenhagen , Denmark. 2005.

- M. Barcia-Macay, M.P. Mingeot-Leclercq, P.M. Tulkens,* F. Van Bambeke. Pharmacological comparison of antibiotics against intracellular S. aureus. O120.

- E. Ampe* Y. Glupczynski, P.M. Tulkens, F. Van Bambeke. Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals and students. P878.

- M. Heremans, M.P. Mingeot-Leclercq, P.M. Tulkens,* F. Van Bambeke. Ciprofloxacin (CIP) accumulation and intracellular activity against L. monocytogenes are reduced in ciprofloxacin-resistant macrophages due to increased efflux. P1100.

- N. Mesaros, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens*. Phenotypic and genotypic detection of 3 Mex efflux pumps in P. aeruginosa.. P1731.

36. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. 2005.

- H. Servais, Y. Jossin, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens*. Gentamicin (GEN) causes apoptosis at low concentrations in LLC-PK1 cells subjected to electroporation (EP).. A1706

- N. Mesaros, N. Caceres, F. Van Bambeke,* Y. Glupczynski, M.P. Mingeot-Leclercq and P.M. Tulkens. Genotypic method is more reliable than phenotypic characterization to detect Mex efflux pumps in clinical isolates of Pseudomonas aeruginosa. D1699

- S. Lemaire,* F. Van Bambeke, M.-P. Mingeot-Leclercq, Y. Glupczynski, P.M. Tulkens. Carbapenems are active against intracellular MRSA.. A1832

- M. Barcia-Macay, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke.*Telavancin (TEL) accumulates in cultured macrophages and is active against intracellular S. aureus. A1831

37. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France. 2006.

- M. Barcia-Macay, M.P. Mingeot-Leclercq, P.M. Tulkens,* F. Van Bambeke.. Pharmacodynamic evaluation of the bactericidal activity of telavancin (TLV) against extracellular and intracellular MSSA and MRSA. oral presentation O356

- S. Lemaire, F. Van Bambeke, P.M. Tulkens,* M.P. Mingeot-Leclercq, J. Coyette, Y. Glupczynski.. Meropenem and cloxacillin are active against MRSA clinical isolates (including VISA) in acidic broth and in THP-1 macrophages. Poster P1534


- N. Mesaros, Y. Glupczynski, D. Pierard, A. Dediste, Y. Van Laethem, P.M. Tulkens,* M.P. Mingeot-Leclercq, F. Van Bambeke. Detection of mexA and mexX efflux genes in P. aeruginosa: correlation between QC-RT-PCR and Real-Time PCR. Poster P1751

38. 12th International Symposium on Staphylococci & Staphylococcal Infections, Maastricht, The Netherlands. 2006.

- P. Baudoux,* N. Bles, S. Lemaire, M.-P. Mingeot-Leclercq, P. M. Tulkens, F. Van Bambeke. Contrasting effect of acid pH on the extracellular and intracellular activities of gentamicin and oxacillin against Staphylococcus aureus. Poster no. P-002

- S. Lemaire,* P. Baudoux, M. Barcia-Macay, F. Van Bambeke, Y. Glupczynski, P.M. Tulkens. Intracellular activity of antibiotics against methicillin-sensitive, hospital-acquired methicillin-resistant, and vancomycin-intermediate Staphylococcus aureus (MSSA, HA-MRSA, and VISA) in human macrophages (THP-1) . Poster no. P-004

- Olivier,* S. Lemaire, M.P. Mingeot-Leclercq, F. Van Bambeke, P.M. Tulkens.. Intracellular infection of THP-1 human macrophages by Staphylococcus aureus and role of haemolysins. Poster no. P-021

39. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. 2006.

- L. Avrain, N. Mesaros, Y. Glupczynski, F. Van Bambeke,* R. Vanhoof, and P.M. Tulkens. Mechanisms of resistance in S. pneumoniae exposed to half MICs of ciprofloxacin and moxifloxacin. Poster C1-0041

- M. Barcia-Macay, S. Lemaire, M.-P. Mingeot-Leclercq, P.M. Tulkens, and F. Van Bambeke.* Telavancin is more bactericidal than vancomycin against both extracellular and intracellular (THP-1 macrophages). Staphylococcus aureus with different resistance phenotypes. Poster A-0642

- S. Lemaire*, T. Bogdanovitch, S. Chavez-Bueno, P.D. Savage, F. Van Bambeke, P. Appelbaum, and P.M. Tulkens. Bactericidal activity of ceragenin CSA-13 against intracellular MSSA, hospital-acquired (HA) and Community-acquired (CA) MRSA, and VISA in THP-1 macrophages: relation to cellular toxicity ? Poster A-0633

- S. Lemaire,* F. Van Bambeke, Y. Glupczynski, P. C. Appelbaum, and P.M. Tulkens. Intracellular MRSA, VISA and VRSA are sensitive to cloxacillin and meropenem. Poster A-0634

- Lismond, P. Courvalin, M.-P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke.* Synergy between bacterial Lde and macrophage MRP efflux pumps markedly reduces the activity of ciprofloxacin but not that of moxifloxacin against intracellular Listeria monocytogenes. Poster A-1108

40. 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) & 27th International Congress of Chemotherapy, Munich, Germany. 2007.

- P. Baudoux, Y. Glupczynski,* P.M.Tulkens, F. Van Bambeke.* Extracellular and intracellular activities of Quinupristin-Dalfopristin (Synercid) against S. aureus, with different resistant phenotypes (MSSA, MRSA, VISA). - Poster 2058

- F. Clesse, M.-P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke.* Ciprofloxacin and doxorubicin are substrates of different Multidrug Resistance-related Proteins efflux transporters in J774 macrophages. Poster 2067

- S. Lemaire, F. Van Bambeke, and P.M. Tulkens.* Intracellular activity of daptomycin against methicillin-sensitive, methicillin-resistant, and vancomycin-intermediate S. aureus. - Poster 829

- S. Lemaire, F. Van Bambeke, and P.M. Tulkens.* Inhibitors and activator of the P-glycoprotein efflux pump modulate the accumulation of daptomycin in THP-1 macrophages and its intracellular activity towards S. aureus. O429

- S. Lemaire, F. Van Bambeke, P.M. Tulkens*and Y. Glupczynski. Comparative activity of moxifloxacin, linezolid, cloxacillin, clindamycin, trimethoprim-sulfamethoxazole, and ciprofloxacin against intracellular Methicillin-sensitive and Community-Acquired Methicillin-Resistant S. aureus. Poster 703

- N. Mesaros, Y. Glupczynski, D. Pierard, A. Dediste, Y. Van Laethem, F. Jacobs, M. Struelens, D. De Vos, J.-P. Pirnay, F. Van Bambeke* P.M. Tulkens.. Prevalence of Mex-mediated resistance in P. aeruginosa isolates from patients with ventilator-associated pneumonia in 4 Belgian hospitals. Poster 1358

- S. Denamur, F. Van Bambeke, M.-P. Mingeot-Leclercq, P.M. Tulkens.* Aminoglycoside-induced apoptosis in cultured renal (LLC-PK1) and non-renal (J774 macrophages) cells: comparison between gentamicin and amikacin. - O428

41. Federation of the European Biochemical Societies (FEBS), Vienna, Austria, 2007. - N. E. Caceres,*M. Aerts, M. P.Mingeot-Leclercq, R. Wattiez, P.M. Tulkens, B.Devreese, and F. Van Bambeke.

Evaluation of Macrophage Cell Membrane Preparation for Proteomics Analysis - (Poster E-11)

42. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago,IL. 2007.

- L. Avrain, M. Garvey, Y. Glupczynski, N. Mesaros, M. P. Mingeot-Leclercq, L. J. V. Piddock, P. M. Tulkens, R. Vanhoof, F. Van Bambeke* Ciprofloxacin selects for PatA/PatB over-expression in a wild-type and PmrA-overproducer S. pneumoniae exposed to half-MIC concentrations - (Poster C1/110)

- F. Huyghe, M.P. Mingeot-Leclercq, B. Marquez-Garrido, P. M. Tulkens, F. Van Bambeke.* Competition between ciprofloxacin and non-steroidal anti-inflammatory drugs for efflux transporters in J774 macrophages - (Poster A1141)

- S. Lemaire, L. M. Koeth, H. Labischinski, K. Kosowska-Shick, F. Van Bambeke, P. M. Tulkens* P. Appelbaum. Insufficient activity of most common antistaphylococcal antibiotics towards intraphagocytic forms of S. aureus isolates from a patient with persistent bactereriemia: a cause for treatment failure ? - - (Poster A1439)


- S. Lemaire, F. Van Bambeke, Y. Glupczynski, P. M. Tulkens.* Intraphagocytic activities of ceftobiprole vs. conventional cephalosporins against methicillin-sensitive (MSSA) and methicillin-eesistant S. aureus (MRSA) (Poster A1438)

- H. A. Nguyen,*O. Denis, A. Vergison, P. M. Tulkens, M. Struelens, F. Van Bambeke. Comparative intracellular activity of ten antistaphylococcal antibiotics against a stable Small Colony Variant (SCV) of S. aureus in a model of human THP-1 macrophages - (Poster A1437)

43. 27ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse (RICAI), Paris, France. 2007

- H.A. Nguyen,*O. Denis, A. Vergison, P.M. Tulkens, M. Struelens, F. Van Bambeke. Comparative intracellular activity of 11 antistaphylococcal antibiotics against a stable, thymidine-dependent small colony variant (SCV) and a normal phenotype isolate from a cystic fibrosis patient. Poster no. 325

- S. Lemaire, F. Van Bambeke, Y. Glupczynski, P.M. Tulkens.* Intracellular activity of moxifloxacin against European, American and Asian clinical isolates of community-acquired methicillin-resistant S. aureus (CA-MRSA).. Poster no. 487

- S. Denamur, F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens. 2007. Apoptosis induced by aminoglycosides in cultured cells: comparison between gentamicin and amikacin using incubated and electroporated cells. . Poster no. 503

- Lismond, F. Van Bambeke,*S. Carbonnelle, F. Jacobs, M. Struelens, J. Gigi, A. Simon, Y. Van Laethem, A. Dediste, D. Pierard, P.M. Tulkens. Epidemiological survey of antibiotic resistance in a Belgian collection of CAP isolates of Streptococcus pneumoniae. Poster no. 557

44. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 2008.

- S. Lemaire*, F. Van Bambeke, J.P. Pirnay, G. Verween, P. De Corte, D. De Vos, P.M. Tulkens. Intracellular activity of antibiotics against Staphylococcus aureus internalised human skin keratinocytes: comparison with THP-1 macrophages. Oral session O143

- S. Lemaire,* F. Van Bambeke, M.P. Mingeot-Leclercq, P.M. Tulkens MDR1 (P-glycoprotein) and MRP1 (multidrug resistance-related protein 1) eukaryotic efflux transporters do not affect the cellular accumulation and intracellular activity of tigecycline towards intraphagocytic Staphylococcus aureus. Oral session O147

- H.A. Nguyen, O. Denis, A. Vergison,P.M. Tulkens, M.J. Struelens, F. Van Bambeke*. Activity of antibiotic combinations towards intracellular small colony variants of Staphylococcus aureus in a model of THP-1 macrophages. P1059

- A. Olivier, F. Van Bambeke*, M.P. Mingeot-Leclercq, P.M. Tulkens. Identification of a Staphylococcus aureus strain with increased intracellular growth and reduced intracellular susceptibility to gentamicin. P1060

- H.A. Nguyen, O. Denis, A. Vergison, P.M. Tulkens, M.J. Struelens, F. Van Bambeke*. Intracellular activity of antibiotics against a stable small colony variant of Staphylococcus aureus isolated from a CF patient in model Calu-3 human airway epithelial cells. P1058

- A. Lismond,* F. Van Bambeke, S. Carbonnelle, F. Jacobs, M.J. Struelens, J. Gigi, A. Simon, Y. Van Laethem, A. Dediste, D. Pierard, A. De Bel, P.M. Tulkens. Epidemiological survey of resistance to beta-lactams (AMX, CFX, CRO), macrolides (CLR, TEL), and fluoroquinolones (LVX, MXF) in a Belgian collection of community-acquired pneumonia isolates of Streptococcus pneumoniae. P1747

45. 8th Sienna Meeting- From genome to proteome: integration and proteome completion, Sienna, Italy. 2008.

- M. Aerts,* N. Caceres, J. Van Beeumen, P.M. Tulkens, F. Van Bambeke and B. Devreese . Proteomic analysis of ciprofloxacin-resistant murine macrophages.

46. Membrane trafficking in global cellular responses (The 2008 Golgi meeting), Pavia, Italy, 2008.

- H. Bensikaddour*, P.M. Tulkens, F. Van Bambeke, and M.-P. Mingeot-Leclercq. Determination of the lipid membrane composition of J774 macrophages cells surexpressing MRP proteins (resistant to ciprofloxacin). Poster no. 4H

47. 2d World Conference on Magic Bullets (Ehrlich II),Nuremberg, Germany, Oral presentation. 2008.

- S. Lemaire*, F. Van Bambeke, PM Tulkens. Magic activity of beta-lactams against intracellular Methicillin-Resistant S. aureus: role of acidic pH.

- H.A. Nguyen*, O. Denis, A. Vergison,P.M Tulkens, M. Struelens, F. Van Bambeke. In vitro pharmacodynamic evaluation of intracellular activity of antibiotics alone or in combination against a small colony variant (SCV) of Staphylococcus aureus, Oral presentation

- B. Marquez*, P.M. Tukens, F. Van Bambeke. Can we make eucaryotic cells resistant to antibiotics ? Correlation between Multidrug Resistance-associated Protein (Mrp) efflux pump expression and fluoroquinolones accumulation in J774 macrophages. Oral presentation

48. 6ème Colloque ABC franco-belge / 6th edition of the French-Belgian ABC meeting, Paris, France, 2008.

- B. Marquez *, N.E. Caceres, M.-P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke. Active transport of ciprofloxacin in murine macrophages. Oral presentation


49. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) & 46th Annual meeting of the Infectious Diseases Society of America (IDSA), Washington, DC. 2008.

- B. Marquez, N. E. Caceres, M. P. Mingeot-Leclercq, P. M. Tulkens, F. Van Bambeke*. dentification of the efflux transporter of ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. A-045

- H. A. Nguyen, T. D. Huang, P. M. Tulkens, F. Van Bambeke,* Y. Glupczynski. SCV phenotype and reduced intracellular activity of antibiotics: a cause for persistent staphylococcal infection ? A-970

- P. Baudoux, P. M. Tulkens, F. Van Bambeke *. Intracellular activity of oritavancin against MSSA, MRSA and VISA strains in a model of human macrophages. A-971

- H.A. Nguyen, O. Denis, A. Vergison,P.M. Tulkens, M.J. Struelens, F. Van Bambeke*. Subcellular localisation of S. aureus Small Colony Variant (SCV) versus its normal phenotype counterpart in a model of Calu-3 airway epithelial cells: impact on the intracellular activity of oritavancin, gentamicin, oxacillin and moxifloxacin. A-972

- S. Lemaire*, P. M. Tulkens, F. Van Bambeke. CEM-101, a novel macrolide/ketolide, shows improved intracellular activity against phagocytized S. aureus in comparison with azithromycin, clarithromycin, or telithromycin. A-995

- S. Lemaire,* P. M. Tulkens, F. Van Bambeke. Influence of inhibitors of P-glycoprotein (P-gp) and Multidrug Resistance-associated Protein (MRP) on the accumulation and intracellular activity of CEM-101, a novel macrolide/ketolide, in human THP-1 macrophages: comparison with azithromycin. A-996

- O. Domenech, F. Van Bambeke*, P. M. Tulkens, M. P. Mingeot-Leclercq. Comparative study of membrane permabilization induced by oritavancin vs. vancomycin in liposomes: importance of the acidic character of the membrane. C1-199

50. 53d Annual Meeting of the Biophysical Society, Boston, MA., 2009.

- H. Bensikaddour,* P.M. Tulkens, F. Van Bambeke, M.P. Mingeot-Leclercq. Lipid membrane composition of J774 macrophages cells surexpressing MRP protein (resistant to ciprofloxacin) as compared to wild type. Poster B-655.

51. 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Helsinki, Finland. 2009.

- L. Garcia*, B. Marquez, S. Carryn, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke. Competition between ciprofloxacin and antiviral agents (adefovir, saquinavir, ritonavir) for efflux transporters in J774 macrophages. oral presentation - 023

- S. Lemaire, P.M. Tulkens, F. Van Bambeke. The novel oxazolidinone radezolid (RX-1741) accumulates in THP-1 macrophages: comparative studies with linezolid and azithromycin. oral presentation - 029

- S. Lemaire*, PM. Tulkens, F. Van Bambeke. Radezolid (RX-1741), a novel oxazolidinone, is active against intracellular S. aureus, L. monocytogenes and L. pneumophila phagocytosed by human THP-1 macrophages. oral presentation – 030

- F. El Garch, A. Lismond, F. Van Bambeke*, P.M. Tulkens. Inducibility of PatA/PatB efflux pumps by fluoroquinolones in Streptococcus pneumoniae. 1 oral presentation- O495

- A. Olivier, S. Lemaire, F. Van Bambeke,* P.M. Tulkens, E. Oldfield. Role of rsbU and staphyloxanthin in intracellular growth of Staphylococcus aureus in human phagocytic cells (THP-1 macrophages) . P735

- A. Lismond,* S. Carbonnelle, F. Van Bambeke, P.M. Tulkens. MIC distribution and efflux of 4 respiratory fluoroquinolones (gemifloxacin, garenoxacin, moxifloxacin, levofloxacin) towards S. pneumoniae isolated from patients with confirmed CAP in a country with large fluoroquinolone use (Belgium). P1068

- S. Lemaire*, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P.M. Tulkens. TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolid-resistant S. aureus. P1092

- Lismond,* F. Van Bambeke, P.M. Tulkens. Comparative activities of the novel ketolide CEM-101 and telithromycin towards towards Streptococcus pneumoniae resistant to macrolides from patients with confirmed community-acquired pneumonia. P1099

- M. Riou*, S. Carbonnelle, L. Avrain, Y. Glupczynski, D. Devos, J.-P. Pirnay, A. Simon, D. Pierard, F. Jacobs, A. Dediste, F. Van Bambeke, P.M. Tulkens. Prevalence and epidemiology of antibiotic resistance in Pseudomonas aeruginosa isolated from low respiratory tract of patients hospitalized in intensive care units from 5 Belgian hospitals, 2004-2008. P1502

52. 26th International Conference on Chemotherapy (ICC), Toronto, ON. 2009.

- S. Lemaire, F. Van Bambeke,* P.M. Tulkens. Pharmacodynamic evaluation of the Intracellular activity of CEM-101, a novel ketolide, towards Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. P-70

- M. Riou, S. Carbonnelle, L. Avrain, J.P. Pirnay, D. De Vos, A. Simon, D. Pierard, F. Jacobs, Anne Dediste, F. Van Bambeke, P.M. Tulkens* Antibiotic resistance of clinical isolates of Pseudomonas aeruginosa (PA) collected from Intensive Care Units (ICU) patients with nosocomial pneumonia in 5 Belgian hospitals during the 2004-2008 period using EUCAST breakpoints. P-113

- S. Lemaire, P.M. Tulkens, F. Van Bambeke*. Radezolid (RX-1741), a novel oxazolidinone, accumulates extensively within human macrophages and PMNs and shows activity towards intracellular linezolid-sensitive and linezolid-resistant Staphylococcus aureus . . Oral presentation

- S. Carbonnelle, A. Lismond, F. Van Bambeke, P.M. Tulkens* . Analysis of guidelines for treatment of Community acquired pneumonia (CAP) in outpatients. P-315


1. 34th Federation of the European Societies of Biochemistry (FEBS) meeting - Life's molecular interactions. Prague, Czech Republic. 2009. - B. Marquez*, N. E. Caceres, M. Aerts, C. Vallet, M-P. Mingeot-Leclercq, P.M. Tulkens, B. Devreese, F. Van

Bambeke. Phenotypic, genotypic and proteomic characterization of J774 macrophages upon chronic exposure to fluoroquinolone antibiotics. Poster 4-84

54. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. 2009.

- M. Riou, S. Carbonnelle, D. De Vos, A. Simon, F. Van Bambeke*, P. M. Tulkens. Susceptibility of Pseudomonas aeruginosa to biocides among clinical isolates collected from Intensive Care units patients with nosocomial pneumonia in 5 Belgian teaching hospitals during the 2004-2008 period.. C2-628

- P. Baudoux, H. A. Nguyen, O. Domenech, M. P. Mingeot-Leclercq, F. Van Bambeke,* P. M. Tulkens. Oritavancin kills S. aureus by increasing membrane permeability without causing extensive cell lysis: comparative studies with vancomycin, daptomycin, and lysostaphin. C1-1354

- S. Lemaire*, F. Van Bambeke, P.M. Tulkens. Contrasting effect of acidic pH on the bactericidal activities of CEM-102 (fusidic acid) vs. linezolid and clindamycin towards Staphylococcus aureus . C1-1928

- S. Lemaire*, F. Van Bambeke, P.M. Tulkens. Torezolid (TR-700), a novel methyltetrazolyl-oxazolidinone, accumulates markedly within human THP-1 macrophages and shows activity towards intraphagocytic Legionella pneumophila: comparison with linezolid. A1-1934

- S. Lemaire*, K. Kosowska-Shick, P.C. Appelbaum, J. Pirnay, G. Verween, G. Verbeken, D. De Vos, P.M. Tulkens, F. Van Bambeke. Accumulation and intracellular activity of radezolid, a new oxazolidinone, in non-phagocytic cells. A1-1936

- S. Lemaire*, K. Kosowska-Shick, P.C. Appelbaum, P.M. Tulkens, F. Van Bambeke. Radezolid, a new oxazolidinone, is active against intraphagocytic Staphylococcus aureus with various resistance phenotypes in a model of THP-1 human macrophages. A1-1937

- S. Lemaire*, F. Van Bambeke, P.M. Tulkens. Cellular accumulation and intracellular activity of finafloxacin (FNX), a novel fluoroquinolone (FQ) with enhanced activity at acid pH, against S. aureus and L. pneumophila: comparison with ciprofloxacin and moxifloxacin. A1-1940

55. Signal Transduction and Disease” (a joint meeting of the Biochemical societies of Belgium, the Netherlands and Germany). Aachen, Germany, 2009.

- C. Vallet*, B. Marquez, N. Nhiri, E. Jacquet, M-P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke. 2009. Changes in the expression of MDR transporters in J774 mouse macrophages selected by chronic exposure to ciprofloxacin or moxifloxacin, two fluoroquinolone antibiotics. poster.

56. 9th Annual meeting of the International Society of Pharmacovigilance (ISoP): "From Pharmacovigilance to Risk Management", Reims, France. 2009.

- S. Carbonnelle*, F. Van Bambeke, P.M. Tulkens. 2009. Critical Analysis of the Risk/Benefit Ratio of First Line Antibiotics Included in Guidelines for the Treatment of Community-Acquired Pneumonia. Poster no. 375

57. 29ème Réunion Interdisciplinaire de Chimiothérapie Anti-infectieuse, Paris, France, 2009

- S. Lemaire,* F. Van Bambeke, P.M. Tulkens. Etude de l'activité d'antibiotiques vis-à-vis des formes intracellulaires de Staphylococcus aureus et Legionella pneumophila. présentation orale

- S. Lemaire,* F. Van Bambeke, P.M. Tulkens, D. Piérard. Sensibilité d'isolats récents de S. aureus résistant à la méthicilline (SARM) vis-à-vis de la vancomycine (VAN), de la quinupristin/dalfopristin (Q-D), et du ceftobiprole (BPR) dans un centre hospitalo-universitaire belge. Affiche n° 327

- M. Riou,* F. Van Bambeke, P.M. Tulkens, J. Broughal. Etude comparative de la sensibilité au doripénème, à l'imipénème et au méropénème de souches de Pseudomonas aeruginosa collectées chez des patients souffrants de pneumonie nosocomiale dans 5 hôpitaux belges (2004 - 2008). Affiche n° 348

- M. Riou,* Y. Glupczynski, S. Carbonelle, L. Avrain, J. Pirnay, D. De Vos, A. Simon, D. Pierard, F. Jacobs, A. Dediste, F. Van Bambeke, P.M. Tulkens . Impact du traitement antibiotique sur le niveau de résistance des souches de Pseudomonas aeruginosa collectées par paires sur des patients souffrant d'une pneumonie nosocomiale dans cinq hôpitaux belges. Affiche n° 427

58. 3d FEBS Special Meeting - ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases, Innsbruck, Austria, 2010

- L. Garcia,* B. Marquez, J. Buyck, M.P. Mingeot-Leclercq, P.M. Tukens, F. Van Bambeke. Influence of two ABC transporters, ABCC4 and ABCG2, on ciprofloxacin accumulation in teh context of cystic fibrosis. Poster.

- C. Vallet,* B. Marquez, N. Nhiri, M-P Mingeot-Leclercq, P.M. Tulkens, E. Jacquet, F. Van Bambeke. Expression and functionality of ABC transporters in J774 macrophages selected by chronic exposure to ciprofloxacin or moxifloxacin, two fluoroquinolone antibiotics. poster


59. 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 2010

- M. Riou, L. Avrain, F. El Garch, Y. Glupczynski, J.P. Pirnay, D. De Vos, P.M. Tulkens, F. Van Bambeke*. Influence of antibiotic treatments on gene expression of RND efflux pumps in successive isolates of Pseudomonas aeruginosa collected from patients with nosocomial pneumonia hospitalized in intensive care units from Belgian teaching hospitals. Poster P 780

- A. Lismond, M.I. Garvey, F. El Garch, S. Delvigne, P.M. Tulkens, L.J. Piddock, F. Van Bambeke*. Respective contribution of PatA/PatB and PmrA in fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Poster P 922

- S. Lemaire, P. de Galard, P.M. Tulkens, M.P. Mingeot-Leclercq, F. Van Bambeke.* Phagocytic activity and production of reactive oxygen species in J774 mouse macrophages exposed to increasing concentrations of oritavancin: comparison with vancomycin and azithromycin. Poster P 1585

- J. Buyck,* P.M. Tulkens, F. Van Bambeke. Pharmacodynamic evaluation of the intracellular activity of tobramycin, doripenem, levofloxacin, and colistin towards Pseudomonas aeruginosa after phagocytosis by human THP-1 macrophages. Oral presentation O 518

60. FEBS Workshop: "Microbial Lipids: from genomics to lipidomics", Vienna, Austria, 2010

- H. Bensikaddour,* M. Fillet, Paul. M Tulkens, F. Van Bambeke, M.-P. Mingeot-Leclercq. Identification and quantification of ceramide and glucosylceramide in Murine J774 macrophages cells wild type and Ciprofloxacin resistant cells (CIPR) by liquid chromatography-electrospray ionization tandem mass spectrometry. Poster

- H. Bensikaddour,* P.M. Tulkens, F. Van Bambeke, M.P. Mingeot-Leclercq. Physical chemical properties of lipids extracted from J774 macrophages cells wild type and ciprofloxacin resistant cells: Fluidity and membrane potential. Poster

61. International Symposium on Staphylococci and Staphylococcal Infections, Bath, United Kingdom, 2010

- L. Garcia,* B. C. Kahl, K. Becker, R.A. Proctor, S. Lemaire, P.M. Tulkens, F. Van Bambeke. Characterization of the Intracellular Growth of Menadione and Hemin-dependent Small-Colony Variants (SCV) of Staphylococcus aureus in a Model of THP-1 Macrophages: Consequences for Antibiotic Intracellular Activity. poster

- S. Lemaire*, L. Garcia, F. Van Bambeke ;Y. Glupczynski, P.M. Tulkens. Comparative Study of the Phagocytosis and Intracellular Susceptibility to Antibiotics of a Pig-related ST-398 Methicillin-Resistant S. aureus (A-MRSA) vs Hospital-Acquired MRSA in a Model of THP-1 Macrophages. poster

62. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA. 2010

- E. Ngabirano, C. Vallet, S. Lemaire, B. Marquez, P.M. Tulkens, F. Van Bambeke*. Cellular Accumulation is not Predictive of Intracellular Activity for Fluoroquinolones against S. aureus: Comparison of Gemifloxacin with Moxifloxacin and Ciprofloxacin. poster A1-676

- D. Das, F. Van Bambeke, P.M. Tulkens*. Solithromycin (CEM-101), a Novel Fluoroketolide with Exceptional Cellular Accumulation, Localizes in Lysosomes and Induces Phospholipidosis but not Apoptosis and no Change in Reactive Oxygen Species (ROS) Production in Cultured Cells. Comparison with Azithromycin and Gentamicin. poster A1-686

- L. Garcia, B. C. Kahl, K. Becker, R.A. Proctor, S. Lemaire, P.M. Tulkens, F. Van Bambeke.* Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics against Hemin and Menadione-Dependent Small-Colony. Poster A1-678

- S. Lemaire, P.M. Tulkens, F. Van Bambeke* Contrasting Effect of Acidic pH on the Extracellular and Intracellular Activities of Delafloxacin vs Moxifloxacin towards S. aureus. poster A1-677

- J. Buyck,* P.M. Tulkens and F. Van Bambeke. Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media by modulation of Outer Membrane Permeability. poster D-751

- J. Buyck,* P.M. Tulkens and F. Van Bambeke. Pharmacodynamic Evaluation of 11 Antibiotics against Pseudomonas aeruginosa (PAO1) in Broth and in Human THP-1 Monocytes. poster A1-1395

- S. Lemaire, P. de Galard, J. Buyck, P.M. Tulkens, M.P. Mingeot-Leclercq, F. Van Bambeke*. Influence of Oritavancin on Phagocytosis, Generation of Reactive Oxygen Species and Killing of Intracellular S. aureus in Murine and Human Macrophages and Comparison with Azithromycin and Vancomycin. poster A1-1360

63. 8th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Seoul, Korea, 2011.

- T. T. H. Nguyen, Jean-Marie Pages, Y. Glupczynski, F. Van Bambeke, P.M. Tulkens*. In vitro selection of resistance to temocillin in Enterobacter aerogenes. Poster.

64. 21th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) & 27th International Congress of Chemotherapy (ICC), Milan, Italy, 2011 - Q. Tan, T. Nguyen, F. Bilocq, D. De Vos, J. Pirnay, P. Cornelis, F. Van Bambeke, P.M. Tulkens*. Exposure of

Pseudomonas aeruginosa to sub-MIC concentrations of chlorhexidine leads to increased resistance, marked phenotypic changes, overexpression of MexG, and cross-resistance to antipseudomonal antibiotics. Oral presentation O291

- Nobre Machado,* C. Nonhoff, S. Roisin, A. Vergison, F. Van Bambeke, N. Legros, G. Hay, P. Buidin, C. Thiroux, O. Denis. Comparison of chromogenic and selective media for the detection of Staphylococcus aureus and Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients. Oral presentation 0297


- Vallet, J. Buyck, F. El Garch,* P.M. Tulkens, F. Van Bambeke*. Differential recognition of quinolones by efflux pumps in Gram-positive (Staphylococcus aureus, Streptococcus pneumoniae) and Gram-negative (Pseudomonas aeruginosa) bacteria. Poster P725

- S. Lemaire, D. Piérard, F. Van Bambeke, P.M. Tulkens.* Intracellular activity of fusidic acid against clinical isolates of Staphylococcus aureus of increasing MIC. Poster P780

- S. Lemaire, P.M. Tulkens, F. Van Bambeke. * Activity of 9 antibiotics against intracellular forms of S. pneumoniae. Poster P781

- S. Lemaire, P.M. Tulkens, F. Van Bambeke* . Activity of finafloxacin, a fluroquinolone with enhanced activity at acid pH, against intracellular Legionella pneumophila: comparison with azithromycin, clarithromycin, telithromycin, ciprofloxacin and moxifloxacin. Poster P1139

65. 2d Conference "How dead is dead? - The ins and outs of bacterial dormancy", Tübingen, Germany, 2011

- J. Bauer,* P.M. Tulkens, F. Van Bambeke Establishment of a maturing and mature staphylococcal biofilm model suitable for screening of antibiotic activity. poster

66. 51th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 2011

- G. de Laminne de Bex, J. Buyck*, P.M. Tulkens, F. Van Bambeke. Inhibitors of Type Three Secretion System (TTSS) protect against Pseudomonas aeruginosa cellular toxicity by inhibiting the transcription of TTSS. Poster A2-057

- J. Buyck,* P.M. Tulkens, F. Van Bambeke. Increased susceptibility of Pseudomonas aeruginosa to macrolides in biologically-relevant media by modulation of outer membrane permeability and of efflux pump expression. Poster E-139

- D. Das, J. Buyck,* F. Van Bambeke, J. Lorent, M.-P. Mingeot-Leclercq, P. Gobin, W. Couet, P.M. Tulkens. Comparative assessment of antibacterial and cytotoxic effects of colistin, colistin methanesulfonate and polymyxin B using Pseudomonas aeruginosa, macrophages and renal cells, and liposomes. Poster F2-170

- J. Buyck*, P. Plésiat, P.M. Tulkens, F. Van Bambeke. Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin. Poster C1-618

- J. Bauer, P.M. Tulkens, F. Van Bambeke*. A maturing and mature staphylococcal biofilm model for screening of antibiotic activity. Poster E-134 - Session "Staphylococcus" - 9/19/2011 11:15:00 AM

- S. Lemaire, P. M. Tulkens, F. Van Bambeke*. Interferon-gamma potentiates the intracellular activity of rifampin towards intracellular Staphylococcus aureus in human THP-1 macrophages. Poster A1-1750

- L. Garcia, B. C. Kahl, K. Becker, R.A. Proctor,S. Lemaire, P.M. Tulkens, F. Van Bambeke*. Influence of phorbol myristate acetate on cellular accumulation and intracellular activity of antibiotics against against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in human THP-1 cells

- L. Garcia, B. C. Kahl, K. Becker, R.A. Proctor, S. Lemaire, P.M. Tulkens, F. Van Bambeke*. Effect of menadione supplementation on the intracellular growth of a menadione-dependent small-colony variant of S. aureus in a model of THP-1 macrophages: consequences for antibiotic intracellular activity

- J. Buyck,* P.M. Tulkens, F. Van Bambeke. Activity of antibiotic combinations towards intracellular Pseudomonas aeruginosa in a model of THP-1 macrophages. Poster A1-1753

67. 8th Lipidomics meeting "Membranes & Bioactive Lipids", Lyon, France, 2011

- S. Denamur, D. Tyteca, J. Marchand-Brynaert, F. Van Bambeke, P. M. Tulkens, P. J. Courtoy, M.-P. Mingeot-Leclercq.* Lysosomal membrane permeabilization, a key event for apoptosis induced by aminoglycoside antibiotics. poster

68. 25th North American Cystic Fibrosis Conference, Anaheim, CA, 2011

- J. Buyck,* L. Garcia, P.M. Tulkens, F. Van Bambeke. Pharmacodynamic evaluation of antibiotics and combinations against Pseudomonas aeruginosa in broth and in human THP-1 monocytes. Poster.

- L. Garcia,* B. C. Kahl, K. Becker, R.A. Proctor, P.M. Tulkens, F. Van Bambeke. Pharmacodynamic evaluation of the intracellular activity of antibiotics against hemin and menadione-dependant Small-Colony Variant (SCV) mutants of Staphylococcus aureus in a model of activated or not THP-1 cells. Poster.

- L. Garcia,* B. C. Kahl, K. Becker, R.A. Proctor, O. Denis, P.M. Tulkens, F. Van Bambeke. Characterization of the internalization and intracellular persistence of menadione and hemin-dependant Small-Colony Variants (SCV) of Staphylococcus aureus in a model of THP-1 cells and of the human airway epithelial cell Line CFBE41o-. poster.

69. 22d European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London, UK, 2012

- J. Dupont, C. Vallet, P.M. Tulkens, M. Prévost, F. Van Bambeke*. Fluoroquinolone recognition by prokaryotic S. aureus NorA and eukaryotic murine Mrp4 efflux transporters: a combined experimental and structural study. Poster P-1279

- Melard, S Lemaire, P.M. Tulkens, F. Van Bambeke*. Pharmacodynamic analysis of the susceptibility of intracellular methicillin-susceptible, methicillin-resistant and linezolid-resistant Staphylococcus aureus to ceftaroline. Poster P-1602

- J. Bauer, P.M. Tulkens, F. Van Bambeke* . Comparison of anti-MRSA antibiotics (vancomycin, linezolid, daptomycin, rifampin) and anti Gram-positive fluoroquinolones (moxifloxacin, delafloxacin) against MSSA and MRSA in models of young and mature biofilms. Poster P-2057

- N.M. Vandevelde,* J. Bauer, P.M. Tulkens, F. Van Bambeke. Activity of macrolides, ketolides, and fluoroquinolones against S. pneumoniae in an in vitro pharmacodynamic model of biofilm. Poster P-2176


70. 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA, 2012

- L.G. Garcia, S. Lemaire, B. C. Kahl, K. Becker, R.A. Proctor, P.M. Tulkens, F. Van Bambeke*. Menadione-dependent Small-colony Variants of MRSA Are Hypersusceptible to beta-lactams Intracellularly Due to Cooperation Between Vacuolar Acidic pH and Oxidant Species. Poster A-596

- L.G. Garcia, S. Lemaire, B. C. Kahl, K. Becker, R.A. Proctor, O. Denis, P.M. Tulkens, F. Van Bambeke*. Activity of Antibiotics against a Normal Phenotype MRSA and its menD and hemB Mutants on Models of Bronchial Epithelial Cells Expressing Wild-Type, F508del or no CFTR. Poster A-597

- L.G. Garcia, S. Lemaire, B. C. Kahl, K. Becker, R.A. Proctor, P.M. Tulkens, F. Van Bambeke*. Influence of Oxidant Stress on the Activity of Antibiotics against the Extracellular and Intracellular (THP-1 cells) Forms of S. aureus and its Small Colony Variants (SCV) Mutants. Poster A-599

- J. Bauer, M. Hallin, O. Denis, P.M. Tulkens, F. Van Bambeke*. Activity of Anti-Staphylococcal Antibiotics in an in-vitro Model of Biofilm Using Clinical Isolates of S. aureus. Poster A-598

- D. Das, A. Lambert, P.M.. Tulkens, G.G. Muccioli, F. Van Bambeke.* Study of the Cellular Uptake and Subcellular Distribution of the Oxazolidinone Tedizolid (TZD) in Murine J774 Macrophages: Lack of Association with Mitochondria. Poster A-1291

- H. Jacqmin, J.M. Buyck, P.M. Tulkens, F. Van Bambeke*. The Monoclonal Antibody Panobacumab (KBPA101) Improves Pseudomonas aeruginosa Opsonophagocytosis by THP1 Monocytes. Poster A-1278

- J. M. Buyck, S. Lemaire, D. Pierard*, F. Van Bambeke, P. M. Tulkens.* In vitro Activity and Pharmacodynamic evaluation of Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV (DTIs) against Extracellular and Intracellular Forms of ciprofloxacin-susceptible and ciprofloxacin-resistant Pseudomonas aeruginosa and Staphylococcus aureus. Poster F-2029

71. ASM Conference on Biofilms (ASM Biofilms 2012), Miami, Florida, 2012

- N. Vandevelde,* P. M. Tulkens, F. Van Bambeke. Activity of macrolides and fluoroquinolones in models of naive and induced biofilms of Streptococcus pneumoniae. Poster

- W. Siala*, M. P. Mingeot-Leclercq, P. M. Tulkens, F. Van Bambeke. Quantitative and qualitative assessment of antibiotic activity against Staphylococcus aureus biofilm. Poster

72. II International Conference on Antimicrobial Research, Lisbon, Portugal, 2012

- A. Anantharajah,* J.M Buyck, E. Faure, G. de Laminne de Bex; M.P. Mingeot-Leclercq; PM.Tulkens; B. Guery; F. Van Bambeke. INPs (inhibitors of the type III secretion system) reduce virulence of Pseudomonas aeruginosa towards A549 alveolar epithelial cells. abstract 564

- J.M. Buyck*; H. Traore; F. Vanderbist; P.M. Tulkens; F. Van Bambeke. Pharmacological effects of tobramycin/ macrolides combination on extracellular and intracellular infection by Pseudomonas aeruginosa. abstract 565

73 23d European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Berlin, Germany, 2013

- S. Lemaire, R. Leclercq, B. Kahl, F. Van Bambeke, PM. Tulkens*. Catalase activity in Staphylococcus aureus is associated with increased susceptibility to hydrogen peroxide killing and to decreased intracellular growth. Oral presentation O175

- S. Lemaire, M. van der Linden*, F. Van Bambeke, P.M. Tulkens*. Activities of amoxicillin, clarithromycin and moxifloxacin towards intracellular forms of Streptococcus pneumoniae with increasing minimum inhibitory concentrations (MICs): attempt at defining an intracellular susceptibility breakpoint. Oral presentation 608.

74. 28th International Congress on Chemotherapy and Infection (ICC) - Yokoama, Japan, 2013

- D. Das, A. Lambert, P. M. Tulkens*, G. G. Muccioli, F. Van Bambeke. Cell safety and subcellular distribution of the oxazolidinone tedizolid in murine J774 and human THP-1 macrophages. Poster 114.

75. 14th International Conference on Pseudomonas. Lausanne, Switzerland, 2013

- A. Anantharajah*, E. Faure, J.M. Buyck, C. Sundin, T. Lindmark, PM.Tulkens, M.P. Mingeot-Leclercq, B. Guery, F. Van Bambeke. The 8-hydroxyquinoline INP1855 reduces Type Three secretion system (T3SS)-dependent virulence of Pseudomonas aeruginosa in vitro and in vivo. Poster ID 182.

- A. Anantharajah*, E. Faure, J.M. Buyck, PM.Tulkens, M.P. Mingeot-Leclercq, B. Guery, F. Van Bambeke. Type Three Secretion System (T3SS)-mediated internalisation and cytotoxicity of Pseudomonas aeruginosa by epithelial and phagocytic cells : does inflammasome make the difference? Poster ID 214.

- E. Bassères*, J.M. Buyck, H. Traore, P.M. Tulkens, F.Vanderbist, F.Van Bambeke. Activity of tobramycin in combination with clarithromycin against Pseudomonas aeruginosa biofilms in an artificial sputum medium (ASM) model. Poster ID 218

76. 3rd European Congress on Microbial Biofilms, Ghent, Belgium, 2013 - W. Siala*, M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke. Revealing moxifloxacin activity against

biofilms of S. aureus isolated from persistent infections by means of polycationic and amphiphilic substances. Poster.

77. 53d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, CO, 2013

- PM Tulkens*, M van der Linden, F Van Bambeke, R Vanhoof. Activity of solithromycin against S. pneumoniae clinical strains with nonsusceptibility and resistance [EUCAST interpretative criteria] to penicillin G, amoxicillin, ceftriaxone, moxifloxacin, levofloxacin and ceftaroline. Poster C2-201.

- JM Buyck*, C Luyckx, F Van Bambeke, K M Krause, WW Nichols, PM Tulkens. Activity and pharmacodynamic evaluation of avibactam-ceftazidime against extracellular and intracellular forms of ceftazidime-susceptible and ceftazidime-resistant Pseudomonas aeruginosa. Poster A1021.


- J M Buyck, PM Tulkens and F Van Bambeke*. RX-P873, a novel protein synthesis inhibitor, accumulates in human THP-1 monocytes and is active against extracellular and intracellular Pseudomonas aeruginosa. Poster F638

- NM Vandevelde*, Y Diaz Iglesias, PM Tulkens, H Rodriguez-Villalobos, G Liistro, A Boel, K Van Vaerenbergh, P. Jordens, I. Philippart, JP d’Odemont, J Cadrobbi, N Coppens, F Van Bambeke. Relationships between antibiotic susceptibility to beta-lactams, macrolides, and fluoroquinolones of Streptococcus pneumoniae isolated from COPD patients and their ability to produce biofilm in a chronic in vitro model. Poster C2-539.

- JM Buyck*, PM Tulkens and F Van Bambeke. Activity of antibiotic combinations towards intracellular Pseudomonas aeruginosa strains with different resistance phenotypes in a model of THP-1 monocytes. Poster A1049

- NM Vandevelde*, M Van Obbergh, PM Tulkens, J Verhaegen, F Van Bambeke. Co-medications improve moxifloxacin ativity in models of pneumococcal naïve and induced biofilms. Poster A1047.

78. 42nd European Society of Clinical Microbiology (ESCP) Symposium on Clinical Pharmacy; Prague, Czech Republic, 2013

- N. M. Vandevelde*, P. M. Tulkens, I. Philippart, N. Coppens, H. Rodriguez-Villalobos, J. Cadrobbi, G. Liistro, J.-P. d’Odemont, A. Boel, P. Jordens, Y. Valcke, H. Francart, F. Van Bambeke. Chronic obstructive pulmonary disease (COPD): severity risk factors and evaluation of medication use. Poster


Enclosure II: Invited lectures See: http://www.facm.ucl.ac.be/facm-conferences.htm national meetings 1. 24/05/1993:

4° Journée de recherche de l'Ecole de Pharmacie; Bruxelles (Belgique) "Etude des interactions entre un médicament et les membranes biologiques".

2. 13/05/1995: Colloque sur la maladie de Lyme; St Hubert (Belgique) "Bases pharmacodynamiques et pharmacocinétiques du traitement antibiotique de la maladie de Lyme"

3.19/03/1996: Workshop "quinolones: quo vadis?"; Leuven (Belgique) "Structure-activity relationships for quinolone antibiotics"

4. 10/05/1996: Journée de la recherche à l'Ecole de Pharmacie; Bruxelles (Belgique) "Liaison des antibiotiques aux membranes: importance biologique"

5.27/11/1996: Séminaire de Pathologie Infectieuse; Mont Godinne (Belgique) "La maladie de Lyme: pour une approche diagnostique et thérapeutique rationnelle" (séminaire donné en collaboration avec le Dr G. Bigaignon et le Prof. J. Ninane)

6.9/06/1997: Séminaire Interne de l'Unité des Agents Antibactériens (Institut Pasteur, France) "Mécanismes de toxicité cellulaire d'antibiotiques lysosomotropes."

29/01/1998: Séminaire Interne de l'Unité de Biochimie physiologique (UCL, Louvain-La-Neuve, Belgique)

"Les Fluroroquinolones: mécanismes d'accumulation et d'efflux dans des cellules eucaryotes" 7.10/03/1998 Conférence "Midis culturels", Bruxelles (Belgique) "Les antibiotiques: une arme à double tranchant" (en collaboration avec le Prof. P. Tulkens)

8.25/03/1998: Séminaire Interne de l'Unité de Conformation des Macromolécules Biologiques (ULB, Bruxelles, Belgique) "La vancomycine-dépendance chez E. faecalis: relations entre séquence d'acides aminés et activité de la D-Ala-D-Ala ligase"

9.07/05/1998: Journée de la recherche à l'Ecole de Pharmacie; Bruxelles (Belgique) "Résistance aux antibiotiques: adaptation des bactéries au génie de l'homme"


10. 29/06/1998 Séminaire de Pathologie Infectieuse; UCL, Bruxelles (Belgique) "Les nouvelles fluoroquinolones: pourquoi et pour qui?" (séminaire donné en collaboration avec les Prof. M. Delmée et P. Tulkens et le Dr B. Delaere)

11. 29/03/2001 Séminaire de Pathologie Infectieuse; UCL, Mont-Godinne (Belgique) "Pharmacodynamie des antibiotiques: une aide à la prescription efficace ?" (en collaboration avec le Prof. Tulkens) 12. 11/12/2002 Séminaire des maladies infectieuses, ULB, Erasme (Belgique) "Pharmacodynamie des antibiotiques: une aide à la prescription efficace ?" (en collaboration avec le Prof. Tulkens) 13. 13/10/2004 2ème session de la chaire GSK de maladies infectieuses ; workshop interactif pour microbiologistes, Bruxelles (Belgique) « Intracellular S. aureus : what does it mean ? » 14. 13/12/2004 séminaire du département des sciences pharmaceutiques, UCL, Bruxelles “Glycopeptides: how can a structural modification bring to a new life an old family of antibiotics ?” 15. 29/03/2006 symposium interactif : Pseudomonas aeruginosa: resistance and therapeutic options, UCL, Bruxelles "New molecules in the pipeline ?" 16. 11/01/2007 symposium S. aureus: what should the clinician know in 2007 ? UCL, Bruxelles ”The new antistaphycolococcal drugs (tigecycline, daptomycin, telavancin, …) : is the future (really) shining ?” 17. 31/05/2007 Séminaire de Pathologie Infectieuse; UCL, Bruxelles " Les nouvelles molécules anti-MRSA (linézolid, tigécycline, daptomycine, …): livrent-elles ce qu'elles promettent ?" (en collaboration avec le Prof. B. Vandercam) 18. 01/04/2008 Séminaire de Pathologie Infectieuse;Mont-Godinne, Yvoir Bacterial community-acquired respiratory tract infections: Epidemiological, pathological and therapeutic aspects (en collaboration avec le Prof. P.C. Appelbaum) 19.19/11/2008 17ème Conférence de consensus en maladies infectieuses - Prise en charge des méningites bactériennes aiguës, Paris "Pharmacodynamie des antibiotiques dans le liquide céphalo-rachidien (LCR): Principes et conséquences (facteurs prédictifs d'efficacité)" 20.14/05/2009 Réunion scientifique du Service des Soins Intensifs, Cliniques universitaires St-Luc, Bruxelles, Belgique - "Vancomycine et Linezolid: quelle place dans les infections à Gram(+) ?"


21.26/05/2009 Journées d'animation scientifique de l'INRA, port d'Albret, France "Antibiotic efflux in eucaryotic cells" 22.25/01/2010 séminaire de pharmacie clinique, Université catholique de Louvain & Cliniques universitaires St-Luc, Bruxelles "Update on new antibiotics in Belgium" 23. 27/05/2010; 09/06/2010; 27/05/2012; 25/10/2012 séminaire pour le Groupe de gestion de l'antibiothérapie de l'hôpital de la citadelle, Liège; séminaire de maladies infectieuses, hôpital Erasme; séminaire du groupement de réanimateurs d'entre Escaut et Meuse; séminaire des soins intensifs de l'hôpital Saint Luc. "Adaptations posologiques des antibiotiques en cas de BMI extrêmes" 24. 15/02/2012 Institut national de la recherche agronomique (INRA), Tours, France "Intracellular bacteria and antibiotics: S. aureus, L. monocytogenes and P. aeruginosa" 25. 15/02/2012 Institut national de la recherche agronomique (INRA), Tours, France "Antibiotic efflux: from discovery to epidemiological, clinical, and veterinary impact" 26. 25/04/2013 Joint sympopsium of the Belgian Society of Orthopaedica and the Société belge d’infectiologie et de microbiologie clinique, Spa "Antibiotics in bone and joint infections" International meetings 1. 22/11/1994 Symposium sur l'optimisation des conditions d'utilisation des aminoglycosides; Grenoble (France) "Evolution du rythme d'administration, conséquences sur l'efficacité et la tolérance"

2. 23/09/1998 7th Symposium of the International Society for Anti-infective Pharmacology, San Diego, Cal "Cultured cells models for the prospective assessment of anti-infective toxicity"

3. 21/03/1999 1st ISAP Pharmacokinetics / Pharmacodynamics (PK / PD) workshop, Berlin (Germany) "Intracellular anti-infectives: is it important for efficacy and do we need to care for toxicity ?" 4. 03/07/1999 9th Symposium of the International Society for Anti-infective Pharmacology, Birmingham (United Kingdom)

"In vitro toxicodynamic models to accelerate drug selection and safety assessment" 5. 06/10/1999 Case Western Reserve University, Cleveland, OH

"The Pros and Cons of intracellular antibiotics"


6. 01/12/1999 Coût biologique de la résistance aux antibiotiques - Société française de Microbiologie, Institut Pasteur, Paris (France)

"Vancomycine-dépendance: prix ultime bactérien" 7. 28/05/2000 2d ISAP Pharmacokinetics / Pharmacodynamics (PK / PD) Educational Workshop, Stockholm (Sweden)

"The concentration-effect relationships for intracellular micro-organisms drug trapping, antibiotic efflux pumps, intracellular MIC " (en collaboration avec le Prof. Tulkens) 8. 17/09/2000 3d ISAP Pharmacokinetics / Pharmacodynamics (PK / PD) Educational Workshop, Toronto (Canada)

"The concentration-effect relationships for intracellular micro-organisms drug trapping, antibiotic efflux pumps, intracellular MIC " 9. 09/06/2003 23rd International Congress of Chemotherapy, Durban (South Africa) “Pumps, pumps, pumps: does molecular biology open real perspectives in chemotherapy?” 10. 20/10/2003 5th European Congress of Chemotherapy, Rhodes (Greece) “New glycopeptides: from old Mississipi mud to new derivatives: a critical appraisal” 11. 03/05/2004 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague (Czech Republique) satelitte symposium on glycopeptides : “MRSA treatment: is the future shining ?” 12. 28/05/2004 9th management committee of cost action B16 «reversal of antibiotic resistance (by inhibition of trans-membrane transport) », Ghent (Belgium) “Antibiotic efflux pumps in eucaryotic cells: consequences for activity against intracellular infections” 13. 08/06/2005 Journée d’animation scientifique IFR 136 « Agents transmissibles et infectiologie », INRA Tours-Nouzilly (France) : Mécanismes d’efflux et résistances aux agents thérapeutiques « Efflux actif des antibiotiques chez les cellules eucaryotes : conséquences pour leur activité vis-à-vis d'infections intracellulaires » 14. 27/09/2006 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society of Microbiology, San Francisco, CA " Pharmacokinetics of Old and New Glycopeptides" 15. 04/07/2007 Transport across membranes: Multiple drug resistance, mechanisms and new tools. Summer School Jacobs University Bremen, Germany “Molecular bases for antibiotic resistance through efflux” 16. 21/04/2008 European Congress of Clinical Microbiology and Infection (ECCMID), Barcelona, Spain “Activity of antibiotics against intracellular S. aureus “ 17. 25/10/2008 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Diseases Society of America, Washington, DC “How to target intracellular pathogens”


18. 05/10/2008: 2nd World Conference on Magic Bullets (Ehrlich II), Nürnberg, Germany "From erythromycin to telithromycin: two bullets for one target ... what makes the difference ?" 19. 15/01/2009 Séminaire du Institut für Medizinische Mikrobiologie, Universitätsklinikum Münster, Münster, Germany “Deciphering the activity of antibiotics against intracellular Staphylococcus aureus with the help of PK/PD (pharmacokinetics/pharmacodynamics).” 20.20/06/2009 26th International Congress of Chemotherapy and Infection (Meet the Experts session ME-41), Toronto, Ont. "Collateral effects of antibiotics: adverse effects and drug interactions" 21.08/10/2009 ESCMID/FEMS Conference: "From Microbial Pathogenesis to the Discovery of Antivirulence Drugs", Les Diablerets, Switzerland "Efflux pump inhibitors to restore antibiotic efficacy" 22.27/10/2009 ESCMID Conference: " Antibiotic treatment failure in the absence of resistance ", Freiburg, Germany "Antibiotic treatment failure in the absence of resistance as reported by the clinical microbiology laboratory: a pharmacological and clinical perspective" 23.18/03/2010 Gordon Research Conference on New Antibacterial Discovery & Development, Galveston, Texas " Intracellular Killing: Where’s the Bug?/Where’s the Drug?" 24. 09/07/2010 Summer school on Transport across membranes: Multiple drug resistance, mechanisms and new tools, bremen, Germany "How do antibiotics play with multidrug transporters in eucaryotic cells ?" 25. 09/09/2010 Invited Lecture - Department of Chemistry and Biochemistry, University of Notre-Dame, Notre Dame, Indiana "Hunting intracellular bacteria with antibiotics" 26. 13/06/2011 Gordon Research Conference on efflux, Les Diablerets, Switzerland "How do antibiotics play with efflux transporters in mammalian and bacterial cells?" 27. 12/09/2012 Meet-the-expert session - 52d Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA Intra- and Extra-cellular Activities of Anti-Infective Agents 28. 22/03/2013 Bayer symposium on moxifloxacin in respiratory tract infections, Dubai, Emirates “Moxifloxacin: PK/PD and safety profile” 29. 16/09/2013 Invited Lecture - Department of Chemistry and Biochemistry, University of Notre-Dame, Notre Dame, Indiana "Antibiotic resistance by efflux: from molecular aspects to cinical impact"


Enclosure III: PhD students and Master students

PhD students:

- co-promotor

years name Doctoral school title

2004-2008 I. Tytgat (BE) Doctorat en sciences Purification de ligases bactériennes et caracétrisation d’inhibituers originaux

2004-2008 A. Olivier (BE) Doctorat en sciences Rôle de la production de toxines dans la survie intracellulaire de S. aureus

2004-2008 S. Lemaire (BE) Doctorat en sciences pharmaceutiques Etude des facteurs qui modulent l'activité des antibiotiques vis-à-vis du S. aureus intracellulaire

2005-2010 P. Baudoux (BE) Doctorat en sciences Activité des antibiotiques dans des modèles in vitro et in vivo d’infections par S. aureus

2012- L. Catteau (BE) Doctorat en sciences pharmaceutiques Recherche de nouveaux antibiotiques ou de molécules réversant la réistance à partir de sources naturelles

2013- A. Aymerick Doctorat en sciences pharmaceutiques Synthèse et évaluation d'inhibiteurs de la D-ALa-D-Ala ligase bactérienne comme nouveaux antibiotiques

- promotor

years name Doctoral school title

2003-2007 M. Barcia-Macay

(BO)

Doctorat en sciences pharmaceutiques Activity of antibiotics towards extracellular and intracellular Staphylococcus aureus: Pharmacodynamic studies in vitro using a model of human THP-1 macrophages

2007-2012 C. Vallet (FR) Doctorat en sciences pharmaceutiques Characterization of the active efflux of fluoroquinolones in eukaryotic cells

2008-2012 L. Garcia (BE) Doctorat en sciences pharmaceutiques Intracellular pharmacodynamics of antibiotics against small-colony variants of Staphylococcus aureus in in vitro models of professional phagocytic cells

2007-2013 A. Lismond (BE) Doctorat en sciences pharmaceutiques Efflux des antibiotiques comme mécanisme de résistance

2010- N. Vandevelde (BE)

Doctorat en sciences pharmaceutiques Etude de l'activité des antibiotiques vis-à-vis de S. pneumoniae dans des modèles in vitro d'infections chroniques pertinents de la BPCO

2010- A. Bastos (PT) Doctorat en sciences pharmaceutiques Optimisation de l'administration des antibiotiques sur base de leurs propriétés PK:PD

2011- A. Anantharajah (FR)

Doctorat en sciences pharmaceutiques Infection intracellulaire par P. aeruginosa: rôle des transporteurs d'efflux et des facteurs de virulence dans l'induction de l'apoptose et de l'inflammation; évaluation de nouvelles stratégies thérapeutiques

2012- T. Milosevic (RS)

Doctorat en sciences pharmaceutiques Etude de la pharmacocinétique cellulaire des oxazolidinones en lien avec leur toxicité

2013- H. Chalhoub (LB)

Doctorat en sciences pharmaceutiques Témocilline et Pseudomonas aeruginosa : Etude des mécanismes de résistance intrinsèque et acquise

2013- H. Mustafa (MY) Doctorat en sciences pharmaceutiques Développement et évaluation microbiologique, pharmacologique et pharmaceutique de combinaisons d'antibiotiques pour administration sous forme de poudre sèche pour inhalation chez les patients atteints de mucoviscidose

2013- F. Peyrusson (FR)

Doctorat en sciences pharmaceutiques Etude des paramètres déterminant la persistance ntracellulaire des bactréies


- Thesis committees in UCL

name Defense promotor title

J.M. Michot 2007 P. Tulkens Double-edged effect of a MRP- like transporter on pharmacokinetics, pharmacodynamics and toxicodynamics of quinolones antibiotics in macrophages: involvement of a common efflux pathway

N. Matuszak 2011 D. Lambert Synthèse et évaluation pharmacologique d'inhibiteurs de la MAGlipase

B. Pachikian 2012 N. Delzenne Carence nutritionnelle et syndrome métabolique: intérêt des fructanes

E. Dewulf 2013 N. Delzenne Bactéries intestinales en relation avec l'obésité

E . Catry N. Delzenne Effets régulateurs du métabolisme lipidique par les prébiotiques de type fructanes

J.B. Michotte G. Reychler Evaluation de la déposition pulmonaire d'un nébuliseur associé à une VNI à 2 niveaux de pression par une méthode pharmacocinétique

V. Nicolaes J.F. Collet Caractérisation de nouvelles protéines impliquées dans le maintien de l’intégrité de l’enveloppe d’Escherichia coli: une étape vers le développement de nouveaux antibiotiques

G. Dessily V. Haufroid Impact des polymorphismes génétiques de la P-gp sur l'accumulation intracellulaire et la réponse à différents inhibiteurs de tyrosine kinase

C. Beaufay J. Leclercq Evaluation de l’activité antiparasitaire de plantes utilisées en médecin traditionnelle

B. Dhooghe T. Leal Développement et validation de nouvelles stratégies en vue du traitement de la mucoviscidose

J. Lasserre M. Brecx et G. Leloup

New strategies to control dental biofilms and related diseases

- Thesis jurys in other universities

year name university title

2006 S. Vandevuer Université libre de Bruxelles Etude assistée par ordinateur de protéines et de leurs interactions avec des ligands : application a la D-Alanine :D-Alanine ligase et à la P-glycoprotéine

2006 H.A. Nguyen Université Bordeaux 2, France Pharmacodynamie et pharmacocinétique intracellulaires des fluoroquinolones: étuude in vitro sur deux modèles de monocytes et macrophages humains.

2009 K. Bockstael KULeuven, Leuven, Belgium Functional analysis and development of inhibitors of Staphylococcus epidermidis type I signal peptidases

2010 B. Ba Université Bordeaux 2, France Abilitation à diriger les recherches

2011 J. Pasquier Université du Havre, France Mécanismes de la résistance multidrogue par transfert extragénétique de la P glycoprotéine et modulation du volume cellulaire

2012 E. Imbuluzqueta Universidad de Navarra, Pamplona, Espagne

Nostructured biomaterials as a platform for the controlled delivery of antibiotics

2013 A.S. Messiaen UGent, Gent, Belgium Novel therapeutic strategies against Burkholderia biofilms.

2013 N.Bednarska Kuleuven, Leuven, Belgium Targeted Protein Aggregation as a Novel Antimicrobial Strategy

2013 E. Faure Université Lille-2, Lille, France Inplication de la reconnaisance de Pseudomonas aeruginosa par le NLRC4-inflammasome

master students (promotor or co-promotor) année nom programme d'études sujet

1993-1994

L. Depienne étudiant chercheur en Pharmacie Effets des interactions entre aminoglycosides et membranes sur les propriétés membranaires

1993-1994

D. Gérin Licence en Biologie humaine Effet des aminoglycosides sur la capture endocytaire des liposomes par des macrophages J774


1997-1998

S. Burton Licence en technologie biomédicale Etude de l’accumulation d’antibiotiques (fluoroquinolones, -lactames) dans les polymorphonucléaires humains

1999-2000

A.S. Snoeck Licence en Biologie humaine Accumulation et activité intracellulaire du LY333328 dans les macrophages

1999-2000

A. Boucly Licence en Nutrition Mécanisme de l'accumulation de cholestérol induite par l'azithromycine dans des fibroblastes en culture

1999-2000

M.J. Umawahoro

Licence en Nutrition Influence de la composition du milieur de culture sur la capture des fluoroquinolones par des macrophages

2000-2001

P. Cugnon Diplôme d'études complémentaires en sciences biomédicales

Accumulation du LY333328 dans les fibroblastes

2001-2003

M. Barcia-Macay DEA en sciences pharmaceutiques Activité des antibiotiques vis-à-vis de S. aureus extracellulaire et intracellulaire (modèle de macrophages THP-1) infectés

2002-2005

M. Heremans étudiant chercheur en pharmacie Accumulation et efflux des fluoroquinolones dans des macrophages J774 sauvages et résistants à la ciprofloxacine

2004-2005

N. Bles Licences en sciences biomédicales expérimentales

Influence du pH sur la croissance de S. aureus et l’activité des antibiotiques dans des modèles d’infections extracellulaires et intracellulaires

2005-2006

F. Mouaden DES en toxicologie Toxicologie in vitro d'un nouvel antibiotique

de la famille des glycopeptides, la télavancine:

études biochimiques et morphologiques

2005-2006

A. Lismond DEA en sciences pharmaceutiques Activité des quinolones vis-à-vis des formes extracellulaires et intracellulaires de Listeria monocytogenes : modulation par les pompes à efflux bactériennes et eucaryotes

2004-2006

I. Tytgat DEA en biologie Les DD-ligases comme cibles potentielles de nouveaux antibiotiques : purification des enzymes et évaluation préliminaire d’inhibiteurs originaux

2004-2006

A. Olivier DEA en biologie Implication des hémolysines de S. aureus dans le développement de l’infection intracellulaire dans une lignée de cellules phagocytaires

2005-2008

F. Clesse Licence en sciences biomédicales, toxicologie

Implication des transporteurs ABC dans l’efflux de médicaments au niveau des cellules eucaryotes.

2006-2007

F. Huygue Licence en sciences biomédicales, toxicologie

L’efflux actif comme mécanisme d’interactions médicamenteuses : compétition entre fluoroquinolones et AINS pour un même transporteur dans un modèle de macrophages J774

2006-2007

L. Brancovianu Licences en sciences biomédicales expérimentales

Caractérisation des transporteurs effluant les antibiotiques dans des macrophages et des cellules épithéliales MDCK : études de compétition entre la ciprofloxacine (fluoroquinolone) et l’ampicilline (beta-lactame)

2007-2008

L. Garcia Licence en sciences biomédicales, toxicologie

L’efflux actif comme mécanisme d’interactions médicamenteuses : Compétition entre Fluoroquinolones et Antiviraux dans un modèle de macrophages J774

2007-2008

L. Depraetere Baccalauréat en biologie médicale ; IPL Caractérisation de cellules résistantes à la moxifloxacine

2008-2009

R. Simpore Baccalauréat en biologie médicale ; IPL Développement de méthodes phénotypiques et génotypiques pour la détection de la résistance par efflux dans des isolats cliniques de P.aeruginosa

2009-2010

E. Ngabirano Master en sciences biomédicales, toxicologie

Rôle des transporteurs multidrogues (MDR) dans l'accumulation cellulaire d'antibiotiques dans les macrophages J774

2009-2010

M. Safi Baccalauréat en biologie médicale ; IPL Etude le l'activité de CEM-101, un ketolide en développement, sur les formes extra- et intracellulaires de S. pneumoniae

2009-2011

G. de Laminne de Bex

Master en sciences biomédicales expérimentales

Etude de l'activité et du mode d'action d'inhibiteurs du système de sécrétion de type trois sur Pseudomonas aeruginosa

2010-2011

F. Degives Etudiant chercheur en pharmacie Etude des mécanismes de résistance aux fluoroquinolones par efflux actif chez des S.pneumoniae


isolés chez des patients souffrant d'exacerbations de bronchopneumopathies chroniques obstructives.

2010-2011

A. Anantharajah Etudiant chercheur en pharmacie Toxicité des fluoroquinolones et des inhibiteurs de topoisomérases I et II dans des cellules exposées de façon chronique aux fluoroquinolones

2010-2011

M. Gustin Master en sciences biomédicales, toxicologie

Etude de la pharmacocinétique des fluoroquinolones dans un modèle de macrophages humains

2010-2011

B. Valet Baccalauréat en biologie médicale ; IPL Etude du mode d’action de l’oritavancine, un lipoglycopeptide en développement: comparaison avec la vancomycine et la chloroérémomycine

2010-2012

H. Jacqmin Etudiant chercheur en pharmacie Influence du Panobacumab, un anticorps IgM monoclonal, sur la phagocytose de Pseudomonoas aeruginosa par les cellules THP-1

2011-2012

J. Duhoux Baccalauréat en biologie médicale ; IPL Influence de l’azithromycine sur l’expression et l’activité des transporteurs d’efflux et des facteurs de virulence chez Pseudomonas aeruginosa.

2011-2012

S. Wongpramud Baccalauréat en chimle ; IPL Activité des antibiotiques et des biocides sur des biofilms de Staphylococcus aureus.

2010-2012

A. Melard Master en sciences biomédicales expérimentales

Etude de l’activité de la ceftaroline, une nouvelle céphalosporine anti-MRSA, vis-à-vis de formes extracellulaires et intracellulaires de Staphylococcus aureus.

2011-2013

M. Van Obbergh Etudiant chercheur en pharmacie Biofilms de S. pneumoniae chez des patients atteint de bronchopneumopathie obstructive

2011-2013

A. Lambert Master en en sciences biomédicales, toxicologie

Mise au point de dosage des oxazolidinones par HPLC- MS en vue d'évaluer leur pharmcocinétique cellulaire

2012-2013

M. Appelmans Baccalauréat en chimie; IPL Etude de l'activité des antibiotiques sur P. aeruginosa dans du mucus artificiel et en biofilm

2012-2013

C. Luyckx Master complémentaire en pharmacie d'industrie

Etudes pharmacologiques de l'avibactam, un nouvel inhibiteur de beta-lactamase à large spectre

2012-2014

L. Evlard Master en sciences biomédicales, toxicologie

Etude de la toxicité de P. aeruginosa pour les cellules eucaryotes

2012-2014

Y. Diaz Iglesias Master en sciences biomédicales, toxicologie

Influence de la nicotine sur la formation de biofilm par S. pneumoniae et l'activité des antibiotiques

2012-2014

A. Arioua Master en sciences biomédicales, toxicologie

Toxicité cellulaire des oxazolidinones

2013-2015

E. Demazy Master en sciences biomédicales, toxicologie

Pseudomonas aeruginosa et mucoviscidose: virulence, persistence et antibiotiques

2013-2015

G. Huys Etudiant chercheur en pharmacie Pharmacocinétique et pharmacodynamie cellulaires de nouveaux antibiotiques

2013-2015

P. Ngougni Poken

Etudiant chercheur en pharmacie Pharmacocinétique des antibiotiques dans des populations particulières: validation de méthodes analytiques et études pharmacocinétiques

2013-2014

M. Bausart Baccalauréat en chimie; IPL Infleunce du milieu de culture sur l'activité des macrolides vis-à-vis de Pseudomonas aeruginosa

CV F. Van Bambeke; Page 1 of 36 - az-most.ru · CV F. Van Bambeke; Page 1 of 36 ... and treasurer...

Documents

Transcript of CV F. Van Bambeke; Page 1 of 36 - az-most.ru · CV F. Van Bambeke; Page 1 of 36 ... and treasurer...